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1 Introduction 
1.1 Nucleic acid-based therapy  
Nucleic acid-based therapies hold tremendous promise in the treatment of many genetic and 
acquired diseases by delivering therapeutic nucleic acids into patients. The field started 
exploring gene therapy, where genes are transferred to compensate a genetic defect or to 
indirectly mediate a therapeutic effect (“gain of function”). Although gene therapy has not yet 
been established as standard treatment, it was already applied in various clinical studies, 
e.g. in the field of cancer therapy, monogenic diseases (Hemophilia A and B, cystic fibrosis, 
severe combined immunodeficiency syndrome), infectious diseases, vascular diseases, or 
DNA vaccination [1]. Novel strategies include the use of short interfering RNAs (siRNA) for 
knockdown of pathogenic target genes (“loss of function”), antisense oligonucleotides which 
can be used both to suppress [2] or improve gene expression by specific degradation of 
micro RNA [3], and by triggering exon-skipping for partial repair of defective genes [4]. In 
addition various other nucleic acids, such as decoy oligonucleotides [5], aptamers [6] or poly 
inosine-cytosine RNA (polyIC) [7] are in current use. Among those, siRNA mediated RNA 
interference (RNAi) has attracted considerable research interest. Andrew Fire and Craig 
Mello won 2006 the Nobel Prize for their work on RNA interference in Caenorhabditis 
elegans which was published in the year 1998 [8]. Tuschl and his colleagues published 2001 
that synthetic siRNAs can silence target genes in mammalian systems [9]. siRNAs function in 
the cytoplasm and are incorporated into a RNA-induced silencing complex (RISC). When the 
RNA in the RISC complex is complementary to a sequence in a target mRNA, the RISC 
complex guides mRNA cleavage in the middle of the homologous sequence [10]. The RNAi 
discovery is not only used as an established research tool to understand or screen for genes 
functioning in cellular pathways and discover new drug targets, also its potential therapeutic 
application as a new class of pharmaceutical drugs is promising.    
Small-molecule pharmaceutical drugs in general meet Lipinski’s rule-of-five criteria, such as 
high lipophilicity and a molecular weight below 500 [11]. In contrast, nucleic acids naturally 
lack this classical drug like properties. They are negatively charged, extraordinary hydrophilic 
due to their sugar backbone and large macromolecules that do not cross lipid cell 
membranes unaided. Furthermore they are quickly eliminated in the organism by nucleases 
before they reach their target tissue. For their use as (intracellular working) therapeutics 
these properties are not very suitable. Additional many of the established transfection 
methods for in vitro applications cannot be used in most in vivo settings. Clearly, solving the 
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problem of in vivo delivery plays a vital role in the development of nucleic acid-based 
therapies.  
1.2 pDNA and siRNA delivery   
Genes are extensively degraded in plasma. Supercoiled DNA is converted into the open-
circular form with a half-life of 1.2 min upon incubation in isolated rat plasma. The open-
circular form has a half-life of 21 min; the linear form degrades with a half-life of 11 min. The 
clearance from plasma after intravenous administration is even more rapid [12;13]. Tail vein 
injection of naked plasmid DNA into mice resulted in no gene expression in major organs, 
because of clearance by the mononuclear phagocyte system (mainly Kupffer cells in the 
liver) with a disappearance half-life of less than 5 min and its rapid in vivo degradation by 
nucleases, as well as because of limited extravasation [14;15]. Although gene expression 
can be achieved by local delivery of naked plasmid DNA (pDNA), e.g. intramuscular [16] or 
intratumoral injection [17], these facts indicate the importance of a suitable carrier for efficient 
systemic gene delivery.  
Since it is the evolutionary character of viruses to deliver their genes into host cells, they 
present obvious candidates for the development of effective gene delivery vectors. 
Replication-defective viruses, where viral genes were replaced by therapeutic genes, were 
applied as viral vectors in gene therapy. Retroviral vectors and adenoviral vectors have been 
most commonly used in clinical trials [18;19]. Other viruses that were used to develop viral 
vectors include adenoassociated virus, herpes virus and lentivirus [20;21]. One problem of 
viruses is their limited capacity to incorporate the additional therapeutic nucleic acids. 
Besides capacity, activation of the immune system and the possibility of mutagenesis, for 
example caused by retroviral vectors through gene insertion into the host’s genome, are 
severe disadvantages of viral vectors. It’s worth considering that natural evolution designed 
viruses for their propagation and not for safe and efficient gene transfer.  
Synthetic delivery systems (“non-viral vectors”) are more flexible with respect to chemistry 
and nucleic acid type. They can be generated by non-immunogenic peptides or protein free, 
hence there is only bare possibility that patients have high titers of neutralizing antibodies 
against them [22]. However synthetic vectors show in general lower gene transfer efficiency 
after systemic administration in comparison to their viral counterparts.  
Cationic lipid- [23] and polymer-based systems [24;25] are the major types of non-viral 
carriers. Felgner et al. first reported in 1987 on the in vitro transfection of mammalian cells 
with a cation lipid formulation [26]. The lipid formed electrostatic complexes with pDNA, 
named “lipoplexes”. The complex formation is due to ionic interactions between the positively 
charged group on the lipid molecule and the negatively charged phosphate groups on the 
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pDNA. Since then lipid based systems have been extensively studied as gene delivery 
carriers and have even been used in clinical trials [27;28]. 
In 1962 Smull and Ludwig published that the addition of either histone or protamine (both are 
cationic proteins) to poliovirus derived RNA was found to increase the infectivity of the RNA 
on eukaryotic tumor cells. Only when the cationic proteins were mixed with the RNA before 
addition to the cell culture medium, an infection enhancement could be observed [29]. The so 
formed transfection complexes by nucleic acid and cationic polymers were later termed 
“polyplexes” [30]. High molecular weight cationic polymers used as pDNA delivery systems 
include polysaccharides such as chitosan and cyclodextrine, polyaminoacids like poly-L-
lysine (PLL) and polyarginine, polyethylenimine (PEI), dendrimers or polymeric scaffolds [31]. 
PLL has been widely used as a non-viral gene carrier since the formation of polyplexes 
between PLL and pDNA was identified (Fig. 1) [32]. The primary epsilone-amine groups of 
lysine are protonated under physiological conditions and interact electrostatically with 
negatively charged pDNA. Complexation into nanoparticles protects the nucleic acid from 
degradation. The positively charged polyplexes associate with the negatively charged cell 
surface (due to the presence of glycoproteins and glycolipids) and are internalized by the 
cells. Although PLL has some properties suitable for a gene carrier including 
biodegradability, the gene transfer efficiency is rather low: After endocytosis, the PLL 
polyplexes are trapped within the endosome which leads to lysosomal degradation and 
hampers gene expression.  
 
 
 
 
 
 
 
 
Fig. 1: Structures of polyethylenimine (PEI) and polylysine (PLL) 
Over the past decade PEI polymers have evolved into currently the most frequently used 
polycations (Fig. 1) [33]. They contain primary, secondary and tertiary amines which are 
partially protonated in a physiological milieu [34]. The resulting high charge density is ideal to 
compact nucleic acids into nanosized particles [35]. To form small particles in the range of 50 
to 500 nanometers, an excess of PEI nitrogens to DNA phosphates is necessary. As a 
consequence polyplexes have an overall net positive charge. A low PEI nitrogen to DNA 
phosphate ratio (N/P) below 4 leads to the formation a large aggregates [36]. PEI polymers 
can be synthesized with different molecular weights in a linear or branched structure. Both 
linear PEI 
branched PEI 
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paramaters have large influence on the transfection efficiency [37;38]. In contrast to PLL, PEI 
is not degradable but can mediate efficient gene transfer without the use of an additional 
endosomolytic component because it possesses inherent endosome-escape properties. PEI 
containing polyplexes have been used successfully in vivo including nucleic acid transfer in 
brain tumors and lung [7;39].  
The 2001 / 2002 discovery that RNAi is active in mammals was the most exciting technical 
breakthrough in biological research of the last decade. Although non-viral gene delivery 
could up to now not make the breakthrough for pDNA delivery, the long experience in non-
viral gene delivery helped providing several promising proof-of-concept siRNA delivery 
solutions in a relatively short period of time. There are two approaches for bringing siRNA to 
effect. One is to stably express siRNA precursors, such as shRNAs, from pDNA vectors 
using gene therapy; the other is to directly deliver synthetic siRNAs. The latter approach has 
the advantage that delivery into the nucleus is not necessary (one major unsolved problem of 
non-viral pDNA-based gene delivery) and that synthetic siRNAs can be stabilized by 
chemical modifications. siRNAs can be stabilized against nuclease degradation in the 
plasma by introducing phosphorothioate backbone linkages for exonuclease resistance or 2′-
modifications (e.g. 2′-OMe) for endonuclease resistance [40;41]. Current formulations for 
siRNAs include liposomes, lipoplexes, polyplexes and siRNA-conjugates [42;43]. It has to be 
considered that not every system which is effective in pDNA delivery also works for siRNA 
delivery [44;45]. Although locally applied siRNA therapeutics for macular degeneration, 
hepatitis B and respiratory syncytial virus are already in clinical trials and the first phase I 
human trial using systemically applied transferrin-receptor targeted cyclodextrin-containing 
polymer siRNA formulations has been initiated in cancer patients in 2008 [46], further work 
on resolving the challenges of systemic siRNA delivery for all cell types and organs is 
necessary to provide the fullest possible clinical benefit of this technology.  
1.3 Physiological barriers of nucleic acid delivery 
As mentioned, nucleic acid carriers are faced with numerous extracellular and intracellular 
barriers. For reaching distant target sites the vectors should show an elongated plasma 
circulation time. However any particle will be treated like an invading micro-organism. 
Opsonization by serum proteins, mainly by hydrophobic interactions, and following 
phagocytosis by cells of the reticulo-endothelial system will lead to fast clearance. The 
positive charge of polyplexes not only leads to target cell attachment and internalization, it 
also causes unspecific charge-mediated interactions which take place with the ubiquitous 
occurring negatively charged membranes, e.g. of blood components, vascular endothelial 
cells or other non-target tissues. To avoid unspecific interactions, recognition by the immune 
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system and to increase circulation time, the surface of the particles can be modified with 
hydrophilic polymers, e.g. polyethylene glycol (PEG). PEG-lipids have been incorporated into 
lipoplexes [47;48]  and also polyplexes have been PEGylated to reduce the surface charge 
[49;50]. Consequences of PEG grafting of carriers may vary for different nucleic acid types, 
for example siRNA or pDNA complexes. Recently the effect of different molecular weights 
and degrees of PEG substitution on PEI-graft-PEG polymers for pDNA and siRNA delivery 
was evaluated [51]. The researchers revealed that in contrast to the pDNA transfection 
efficiency, siRNA delivery was much less dependent on density and molecular weight of 
PEG-modifications of PEI.  
To reach the site of action within the target cell, the nucleic acid has to stay associated with 
its carrier during the complete extracellular delivery process. As described, conventional 
polyplex and lipoplex formulations are held together electrostatically. A weak point resides in 
the fact that other charged molecules can disrupt such complexes before they reach the 
target cell. Burke et al. demonstrated that both the serum and the extracellular matrix can 
lead to vector disassembly. They observed significant vector unpackaging of systemically 
injected fluorescence-labeled PEI / pDNA polyplexes in the liver, where the labeled DNA was 
found in different areas than the labeled PEI. This obviously negatively affects gene transfer 
efficiency [52]. The work of Buyens et al. reveals the same weak point. They developed a 
method based on fluorescence correlation spectroscopy to study the dissociation of siRNA 
complexes in human serum. The work demonstrates that nonpegylated and pegylated siRNA 
liposome complexes undergo fast disassembly in full serum. Similar observations were made 
for PEI / siRNA polyplexes [53]. Probably vector unpacking is more likely a problem in the 
case of siRNA in comparison with pDNA, as the far larger number of negative charges of 
pDNA stabilizes the interelectrolyte complex [54;55]. To overcome this drawback polymers 
can be crosslinked to cage the nucleic acid in the extracellular environment [56;57] or the 
nucleic acid can be attached covalently [58].  
Selective targeting to cell-type specific tissues can be achieved by incorporation of targeting 
ligands into the delivery vehicles recognizing cell-specific receptors expressed on cell 
surfaces, in order to promote cellular uptake via receptor-mediated endocytosis [59]. After 
cellular association of nonviral vectors, particles are internalized by receptor-mediated 
endocytosis, macropinocytosis, phagocytosis or related processes [60;61]. The 
internalization route resulting in successful gene expression may depend both on polyplex 
type and cell type [62;63].  
For successful nucleic acid delivery, more barriers have to be overcome in the intracellular 
environment. The internalized nucleic acid carriers are mostly found in intracellular vesicles. 
The vesicles fuse to “early endosomes” which have a slight acidic pH of 5.9 – 6. Acidification 
is driven by ATP-dependent proton pumps in the endosomal membrane. When the pH 
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continues to drop to pH 5 – 6, “late endosomes” are formed. Late endosomes function to 
degrade many proteins and lipids but may not be able to digest all the material. Therefore, 
the next step is a fusion of late endosomes and lysosomes. Lysosomes contain digestive 
enzymes including nucleases and are considered to be the end product of endocytosis. 
Hence entrapment in endosomes is associated with degradation of the nucleic acids upon 
endosomal acidification; the release of particles into the cytoplasm represents a major 
bottleneck to nucleic acid delivery. Researchers have started to investigate the intracellular 
kinetics and fate of polyplexes in more detail by single particle tracking [64] and 
computational modeling (in silico transfection). While the internalization step seems to have 
only a moderate impact on the transfection efficiency, endosomal ecape was identified as 
significant rate limiting step [65]. After endosomal release pDNA complexes or free pDNA 
have to traffic through the cytoplasm towards the nucleus. The pDNA has to enter the 
nucleus to reach the transcription machinery. The cytoplasmic trafficking and nuclear import 
process is not clarified yet. Free pDNA could be degraded by nucleases in the cytoplasm, 
hence trafficking is supposed to happen with intact polyplexes by motor proteins [66]. 
Nuclear import of pDNA is another major bottleneck. Transfection of rapidly dividing cells 
where the nuclear envelope breaks down during mitosis is much more easier than 
transfection of non-dividing cells [67]. In case of siRNA, the RISC in the cytoplasm is the 
target location, therefore trafficking towards the nucleus and nuclear import are irrelevant 
processes for siRNA delivery. For siRNA delivery, release of the siRNA in the cytoplasm is 
required by dissociation of the nucleic acid from the electrostatically complexed cationic 
carrier [68]. 
Besides cellular membranes, CpG motifs [69] of the nucleic acid represent a further barrier to 
efficient and sustained gene expression. CpG motifs in the plasmid are agonists for the 
endosomal toll-like receptor 9 and stimulate an inflammatory immune response which 
reduces degree and duration of gene expression. When CpG-free plasmids were used in 
lipid and polymeric pDNA complexes, sustained in vivo gene expression in the absence of 
inflammation could be observed [70;71] .  
In brief, an ideal vector has to fulfill a number of different functions to guide its payload to the 
target location which is different for pDNA and siRNA. It is hard to imagine that one simple 
polymer alone can get the job done. 
1.4 Overcoming endosomal entrapment  
1.4.1 Natural models  
As pointed out, endo-lysosomal degradation represants a major threat for nucleic acid 
delivery. Natural cell invading organisms such as bacteria or viruses have evolved skills to 
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RNA lipid envelope / capsid 
cope with this drawback. Because learning from nature has a long tradition (bionics evolved 
in the 1960s as a framework to pursue the development of artificial systems based on the 
study of biological systems), a few examples are reviewed in this section.   
Influenza virus, like a number of other enveloped viruses, contains a lipid membrane that it 
obtains during maturation by budding from the cytoplasma membrane of an infected cell. The 
membrane contains cellular lipids, but the membrane proteins are coded by the virus. These 
proteins are inserted into the membrane during biosynthesis. Influenza virus has two 
membrane glycoproteins, the hemagglutinin (HA) and the neuraminidase (Fig. 2) [72]. The 
HA is synthesized as a single polypeptide chain, which is subsequently cleaved by removal 
of arginine 329 into two subunits, HA1 (36 kDa) and HA2 (25 kDa). The subunits are 
crosslinked by a disulfide-bond. HA binds to a sialic-acid containing receptor of the target cell 
to initiate internalization of the virus. Influenza virus enters the cell by a endocytotic process. 
Erythrocyte leakage experiments revealed that influenza viruses show high lytic activity at pH 
5.0 to 5.8, depending on the particular virus type [73]. At low endosomal pH, a 
conformational transition of HA is described which results in the activation of membrane-
fusion activity together with a molecular rearrangement that exposes a hydrophobic 
endosomolytic peptide of the HA2 subunit. The observed changes at low pH were also 
detected by electron-microscopy and resulted in a change of HA antigenicity and 
immunogenicity [74], confirming an extensive rearrangement. This triggered membrane-
fusion activity at low pH mediates the endo-lysosomal escape of the virus into the cytoplasm 
which avoids intracellular degradation.    
 
 
 
 
 
 
 
Fig. 2: Illustration of an influenza virus  
 
 
Another organism with endosomolytic features is the bacterium Listeria monocytogenes (Fig. 
3). The ability of Listeria monocytogenes to escape from vacuoles of infected cells and 
subsequently to replicate in the cytosol and spread from cell to cell is one of the individual 
features of this facultative intracellular pathogen. Listeria monocytogenes enters the cell via 
phagocytosis. The bacterium escapes into the cytosol before the phagosome fuses with a 
lysosome. The process of escape is mediated by several proteins. These include the pore-
forming cholesterol- and pH-dependent cytolysin listeriolysin O (LLO) and a phospholipase 
hemagglutinin (HA) 
neuraminidase  
ion channel protein  
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proteins
whose proteolytic activation is mediated by a metalloprotease. LLO is a secretory protein 
which is only produced when Listeria monocytogenes is located within a host.  LLO lytic 
activity has a maximum at pH of 5.5 and rapidly decreases with the increase of the pH. Thus 
it is selectively activated in acidic phagosomes and shows a reduced activity after successful 
release in the neutral cytosol [75].  
 
  
          Fig. 3: Electron micrograph of Listeria monocytogenes bacterium in tissue  
 
 
 
While in the first two described organisms the lytic domain works pH-dependent, the 
adenovirus utilizes a different pH-triggered strategy. Adenovirus is a non-enveloped virus 
with an icosaedric capsid (Fig. 4). The capsid is composed primarily of 240 homotrimeric 
hexon capsomers with 12 penton capsomers located at each of the 12 fivefold axes of 
symmetry. Each penton consists of the fiber protein protruding from the penton base. Further 
capsid components are thought to act primarily as cement proteins that help to stabilize the 
viral particle. The interaction of the penton base with cell surface integrins mediates the 
internalization via clathrin-coated pits [76]. Internalization is thought to trigger capsid 
disassembly and appears to require endosomal acidifcation. The conformational changes 
under acidic conditions lead to partial uncoating of the capsid in the endosome, which is 
necessary for release into the cytosol. During capsid disassembly at low pH, an internal 
capsid protein (protein VI) is exposed. Protein VI containes a N-terminal amphipathic α-helix 
which exhibits a pH-independent lytic activity and induces endosomal membrane penetration 
[77]. 
 
 
 
 
  
 
 
 
 
Fig. 4: Illustration of an adenovirus. Picture: Human adenovirus 2. In: ICTVdB - The Universal Virus 
Database, version 4. Büchen-Osmond, C. (Ed), Columbia University, New York, USA 
 
Changes in physicochemical properties of viruses induced by slight pH differences have 
been also observed in many other types of viruses. Semliki Forest virus, an enveloped virus, 
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gains access to cytosol through reorganization and disassembly of its subunits induced by 
low pH within endosomes. Poliovirus and rhinovirus release its RNA into cytoplasm at acidic 
pH [78;79]. 
In summary, natural organisms consist of different functional components for different 
delivery steps like internalization and endosomal escape. Furthermore it is evident that the 
lytic activity is exhibited in a pH-specific manner which leads to triggered activation in the 
endosomal compartment.  
1.4.2 Artificial approaches  
Some polycations possess considerable buffering properties below the physiological pH, with 
PEI and polyamidoamine polymers leading the way [80]. These polymers are effective gene 
carriers without any modification, e.g. cell targeting ligands or membrane disruption domains. 
PEI containing formulations can promote endosomal escape to a certain degree due to the 
so called “proton sponge” effect. At neutral pH, PEI is only partially protonated: only 
approximately every third nitrogen is positively charged. At acidic pH the secondary amines 
are protonated and the overall protonation level increases [81;82]. During intracellular 
processing in the endosome, the buffering capacity of PEl will not only inhibit the activity of 
the lysosomal enzymes that have an acidic optimal pH, but will also increase the osmotic 
pressure in the vesicle [83]. The accumulation of protons pumped in by the endosomal V-
ATPase is linked to an influx of hydrated chloride ions. Presumably this endosomal swelling 
in combination with membrane-interaction of the polycation induces rupture of the endosomal 
membrane leading to a release of the gene carrier into the cytoplasm. Histidine or rather 
imidazole containing polymers can also exhibit a proton sponge effect and mediate 
endosomal release and efficient gene transfer. The imidazole group of histidine has a pK 
around 6.0 and thus becomes protonated in the acidic endosomal environment. Because 
histidine is not charged at neutral pH, poly-L-histidine was combined with nucleic acid 
binding lysine-domains for the preparation of effective pDNA and siRNA polyplexes [84-86]. 
Recently PEI / pDNA polyplexes were coated with carboxymethyl poly-L-histidine to form 
ternary complexes with improved buffering and membrane disruption capacity. The resulting 
ternary complexes showed gene expression values higher than that of the PEI / pDNA binary 
complexes [87]. But not only polymers with buffering capacity can induce release into the 
cytosol, also several lipid-containing formulations possess endosomal escape properties. 
The membranous nature of the lipoplex seems to be important because it allows the 
exchange of lipids between the endosomal membrane and the lipoplex, which results in 
membrane pertubation [88]. A hexagonal phase formation in lipoplexes appears essential for 
this step, however overall limited insight is available into how endosomal membrane 
destabilization occurs in case of lipoplexes  [89;90]. 
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But despite the proton sponge effect, PEI and related polyplexes demonstrate only inefficient 
endosomal escape. Especially, endosomal escape represents a major bottleneck when only 
small amounts of PEI are accumulated per endosome [91]. To overcome this drawback of 
non-viral nucleic acid delivery, endosomolytic agents were incorporated into nucleic acid 
carriers [92;93]. Natural agents including adenovirus [94], rhinovirus [79], listeriolysin O [95] 
and virus-derived peptides [96-98] have been shown to enhance pDNA and siRNA 
transfection efficiency of polycations. PLL was covalently modified with the N-terminal 
amphiphilic anionic peptides of the influenza virus haemagglutinin subunit HA2. At neutral 
pH, the negatively charged peptide is present in a non-helical conformation. At low 
endosomal pH, protonation causes a transformation to a helical structure, inducing lytic 
activity. The PLL-peptide conjugate showed a higher lytic activity than the free peptide and 
kept its pH-dependent lytic activity. Incorporation of the peptide clearly improved gene 
transfection efficiency [98;99].  
Melittin, a cationic lytic peptide derived from bee venom, has been shown to enhance 
transfection efficiency of lipoplexes and polyplexes in vitro [100-102]. Boeckle et al. found out 
that the site of melittin linkage strongly influenced the membrane lytic activity. PEI was 
covalently attached either to the C-terminus or the N-terminus of melittin, resulting in two 
different conjugates (C-Mel-PEI and N-Mel-PEI). C-Mel-PEI was highly lytic at neutral pH, 
increased doses of C-mel-PEI polyplexes induced high toxicity. In contrast, N-mel-PEI 
showed a reduced lytic activity at neutral pH but maintained a higher lytic activity than C-mel-
PEI at endosomal pH. These differences resulted in better endosomal release of N-Mel-PEI 
polyplexes and efficient gene delivery in different cell lines [103]. For cytosolic delivery of 
cytotoxic double stranded RNA (polyIC; which triggers interferon responses and apoptosis in 
targeted tumor cells) a conjugate was constructed containing the lytic peptide melittin, 
branched PEI for nucleic acid binding and EGF as targeting ligand. The conjugate was 
applied in vivo and facilitated the intracellular delivery of polyIC to glioblastoma tumor [7]. 
Because melittin has inherent lytic activity at extracellular neutral pH, several melittin analogs 
were designed to shift the lytic activity towards the endosomal pH. Acidic modification of 
melittin by replacing neutral glutamines (Gln-25 and Gln-26) with glutamic acid residues  
improved the lytic activity of melittin PEI conjugates at endosomal pH of 5, but lytic activity at 
neutral pH was not reduced [104].  
Synthetic artificial amphiphatic peptides that mimic natural lytic peptides were also designed. 
GALA contains 30 amino acids with a main repeat sequence of glutamic acid-alanine-
leucine-alanine. Protonation of the glutamic acid residues at acidic pH triggers the 
transformation from a random coil to an amphiphatic alpha-helix. The exposed hydrophobic 
domain can interact with lipid bilayers and lead to membrane rupture at acidic pH [105]. 
Recently Harashima and collegues incorporated GALA into transferrin- and PEG-modified 
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liposomes which significantly increased transfection efficiency [106]. KALA is a similar basic 
amphipathic peptide (repeating units of lysine-alanine-leucine-alanine) intentionally designed 
to combine DNA-binding and membrane-destabilizing activities [107]. Self-crosslinking of 
KALA via terminal cysteine-residues resulted in a polypeptide which efficiently bound and 
delivered siRNA [108].    
Beside chemical approaches, physical methods like photochemical internalization can be 
applied to enhance cytosolic delivery of nucleic acids and drugs [109;110]. The technology is 
based on the activation of photosensitizing compounds that are localized in the membranes 
of endocytic vesicles. Upon illumination photosensitizers induce formation of reactive oxygen 
species resulting in rupture of vesicular membranes and release of endocytosed complexes 
into the cytosol. In the initial applications, photosensitizers were applied as separate 
molecules. To ensure the necessary co-localization with the drug after systemic 
administration, recently formulations were developed where the photosensitizer is 
incorporated into the nucleid acid complex [111]. 
In summary, existing data prove that endosomal release is a major barrier of nucleic acid 
delivery. In the past, several chemical and physical approaches have been developed to 
boost the efficiency of synthetic delivery sytems.   
1.5 Design of programmed nucleic acid carriers  
On closer inspection of the complete process of nucleic acid delivery (Fig. 5), the carrier is 
not only faced with various delivery steps and requirements, it even has to fulfill contrary 
functions with time: Outside the cell the nucleic acid has to be stably associated with the 
carrier, but in the cytosol or nucleus the carrier has to release the nucleic acid. The 
endosomal membrane has to be destabilized for efficient delivery, but with regard to toxicity 
outside the endosome, membrane lytic activity is unfavorable. PEG shielding of carriers is 
beneficial for systemic circulation and reduction of undesired interactions. But the advantage 
of shielding is limited to the extracellular environment. Within the endosome, PEGylation may 
hinder lipid membrane interactions of the carrier which might be required for endosomal 
release. The conflicting requirements outside and inside the target cell present a dilemma: 
the surface charge and lytic activity must be shielded in the extracellular environment, but 
after arrival at the target cell and following internalization the lytic activity / the positive charge 
has to be present. Polymers like PEI appear to be a good compromise. They bind pDNA in a 
manner which is stable enough for the extracellular transport but also weak enough for 
intracellular release of their payload. The polymer is positively charged at neutral 
extracellular pH which leads to membrane interaction and internalization, but only in 
combination with the buffering capacity in the endosome the membranes are ruptured. 
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However even the effectivity of such “jack-of-all-trades“-polymers is limited [52;101], a 
compromise seems to be not always the ideal way.  
To handle the described dilemma, the unique functions should be active only during the 
phases of the delivery process were they are required, e.g. the hydrophilic polymer shield 
should be present in the extracellular environment but be removed at the target site. Like 
many viruses, the nucleic acid carriers should sense the environment and dynamically alter 
their properties according to the required tasks [112]. As biological stimuli for programmed 
gene carriers, differences in the pH, the redox-gradient and varying concentrations of specific 
enzymes have been exploited.  
1.5.1 Redox- and enzyme-sensitive systems  
Disulfide bonds are stable in circulation, but are cleaved upon entry into the reductive 
intracellular environment, thus allowing site specific cleavage. siRNA was covalently bound 
to the carrier via a disulfide bond to ensure extracellular stability. The relatively high 
intracellular concentration of the physiological reducing agent glutathione triggers the release 
of the siRNA in the cytosol [58;113]. The difference in redox potential has been also used for 
triggered polymer biodegradation. Linear disulfide crosslinked low-molecular-weight 
polyethylenimine, a biodegradable pendant to linear PEI, was synthesized and displayed 
high efficiency but reduced cytotoxicity [114]. Takae et al. developed PEG-based polyplex 
micelles, which can detach the PEG chains in response to the intracellular reducing 
environment. PEG was linked to the polycation via a cleavable disulfide linkage to form the 
block copolymer. The copolymer formed stably dispersed polyplex micelles with pDNA. After 
treatment with dithiothreitol the polyplex micelles aggregated indicating disulfide cleavage 
followed by PEG detachment. Transfection experiments revealed a superior delivery 
efficiency of the biocleavable PEG-micelles in comparison to the stable PEGylated micelles 
[115].   
Enzyme specific removal of the PEG shield has been exploited by Hatakeyama and 
colleagues [116]. Matrix metalloproteinases (MMPs) are a family of endopeptidases that are 
specially expressed on tumor cells.  As MMP substrate a PEG-peptide-lipid conjugate was 
synthesized and incorporated into a multifunctional envelope-typed nano device. After 
reaching the target cell MMPs cleave the PEG shield which enhanced gene transfer in 
comparison to a non-cleavable PEG shield.   
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Fig. 5: Nucleic acid delivery process using a dynamic bioresponsive (polymeric) carrier  
After association with the target cell via ligand-receptor interaction the carrier is internalized by 
receptor-mediated endocytosis. Acidification during the endo-lysosomal pathway cleaves the shielding 
coat (e.g. PEG) and unmasks a membrane disrupting domain. Next, the carrier is released into the 
cytoplasm. Nucleic acid release of the covalently bound nucleic acid or polymer degradation can be 
triggered by the reductive environment in the cytosol (disulfide cleavage by glutathione). Dependent 
on the type of nucleic acid the site of action is the cytosol (siRNA) or the nucleus (pDNA). 
 
1.5.2 pH-sensitive systems  
For triggered deshielding, also endosomal acidification can be exploited as physiological 
stimulus. Endosomal and lysosomal vesicles exist at pH values between 4.5 and 6.5, in 
contrast to the extracellular neutral pH. The acidic environment has been used to remove the 
PEG coating from liposomal and polymer-based gene vectors [117;118]. Acid cleavable 
bonds include acetals [119], hydrazones [120;121], orthoesters [122;123], thiopropionate 
linkers [124], dialkylmaleic acid monoamides [113] or vinyl ethers [125]. Moreover pH-
triggered deshielding via diffusion could be achieved by use of non-covalently attached 
protective copolymers. Positively charged pDNA or siRNA complexes are ionically coated 
with PEG containing negatively charged molecules which act as anchors. At acidic pH in the 
endosomes protonation of the negatively charged PEG anchors reduces the electrostatic 
interactions and mediates dissociation of the shielding coat from the pDNA or siRNA 
complexes [126;127].   
pH-responsive deshielding elements can be combined with targeting ligands. For example, 
EGF containing PEI-polyplexes were combined with PEG chains attached via pH-sensitive 
hydrazone linkers. The pH-responsive deshielding enhanced gene transfer up to 100-fold in 
vitro compared to stable shielded carriers and also improved tumor specific in vivo transgene 
masked membrane
disrupting domain
active membrane
disrupting domain
pH-responsive linkage
reducible disulfide
bond
target receptor
shielding domain
with targeting ligand
nucleic acid
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expression after intravenous injection [120;121]. Instead of hydrazone linkages also pH-
responsive piperazinobenzaldehyd PEG acetal groups were applied. A novel maleimide-
containing acetal-based PEG reagent was coupled to thiol-functionalized PEI and 
consequently incorporated into polyplexes. Both EGF- and Tf-receptor targeted polyplexes 
enhanced in vitro luciferase gene expression in receptor-expressing target cells as compared 
to their stably shielded analogues [119]. Cleavage of the PEG chains in the endosomal 
vesicles leads to an effective endosomal escape presumably due to interactions between the 
exposed polycation and the negatively charged endosomal membrane. 
Kataoka and colleagues developed a lactosylated PEG-antisense oligonucleotide conjugate 
(Lac-PEG-ODN) containing an acid-labile beta-propionate linkage between the PEG and 
ODN segments. They combined Lac-PEG-ODN with PLL to form polyion complex micelles 
with targeting lactose domains on their surface. It’s worth mentioning that in this case the 
PEG molecule is not coupled to the polycation but to the nucleic acid. The lactosylated 
formulations showed better uptake and antisence effect than the lactose-free formulations on 
hepatoma cells. Without acid-labile linkage the antisense efficiency decreased considerably, 
suggesting that pH-triggered disassembly of Lac-PEG-ODN in the endosome is a key issue 
in the delivery process [128].  
As mentioned above, the lytic peptide melittin enhances the transfection efficiency. 
Unfortunately, melittin displays high lytic activity at neutral pH which has an unfavorable 
effect on the toxicity profile of the polyplexes when administered systemically because lytic 
activity is not restricted to the endosome. Rozema et al. showed how this problem may be 
solved: the primary amines of melittin were modified with a dimethylmaleic anhydride 
derivative, which masks the lytic activity at neutral pH [129]. Following acidification, the 
maleamate shield is cleaved and the lytic activity of melittin is restored. This approach 
showed good results in the delivery of phosphorodiamidate morpholino ODNs (PMOs). 
PMOs are uncharged antisense nucleotide analogues, which are endocytosed but are 
unable to escape from the endosome. The masked melittin and the PMOs were co-delivered 
for the transfection experiments. Co-administration resulted in an increase of antisense 
efficiency in comparison to PMOs alone. These results are promising but for in vivo delivery, 
the membrane-disruptive peptide has to be associated with the vector. The same group 
developed a bioresponsive “PolyConjugate” to deliver siRNA specifically to hepatocytes after 
intravenous injection [113]. The conjugate consisted of a membrane-disruptive polymer 
whose amine groups were modified with a maleic anhydride PEG shielding reagent, 
generating acid-labile maleamate linkages and thus a reversibly masked lytic activity. 
Additional the hepatocyte targeting ligand N-acetylgalactosamine was reversibly attached to 
the polymer via pH-sensitive maleamate linkages. Covalent coupling of the siRNA to the 
carrier via a reductive cleavable disulfide bond ensured extracellular stability and triggered 
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siRNA release in the cytosol. Using this conjugate effective knockdown of two endogenous 
genes in mouse liver (apolipoprotein B and peroxisome proliferator-activated receptor alpha) 
was demonstrated. Besides bioresponsive deshielding and lytic activity, the difference in pH 
can also be utilized to trigger the degradation of polymers for toxicity reduction. Polyplexes 
with acid-labile polymers showed an improved toxicity profile compared to those made with 
acid-stable polymer analogues [130].  
In general shielded complexes with biocleavable linkages showed enhanced nucleic acid 
delivery activity when compared with their corresponding formulations lacking bioresponsive 
linkers. The reviewed approaches highlight the superiority and increasing impact of dynamic 
delivery systems in comparison with their static counterparts [131;132]. 
1.6 Aims of the thesis  
 
The lack of efficient nucleic acid delivery systems still limits the therapeutic application of 
pDNA and siRNA. Poor endosomal release is one major barrier of nucleic acid delivery. 
Endosomolytic polyethylenimine-melittin conjugates exhibited enhanced gene transfer 
efficiency. However, cytotoxicity due to their general membrane destabilizing properties 
restricts their utilization. To overcome this drawback, melittin’s lytic activity can be reversibly 
masked in the extracellular environment. The concept of a reversible acylation of melittin 
through a dimethylmaleic anhydride derivative was presented by Rozema et al. and 
generated a lytic activity triggered only upon acidification [129]. Simultaneous co-delivery of 
the modified peptide and oligonucleotides enhanced cytosolic drug delivery in vitro. However 
melittin does not stably associate with pDNA or siRNA under physiological conditions [102]. 
The first aim of this study was to covalently modify a non-endosomolytic polycation with a 
pH-responsive masked melittin derivate to enhance gene transfer efficiency.  
Dimethylmaleicanhydride modified melittin peptide (DMMAn-Mel) was grafted on PLL and 
the effect of the modification on lytic activity, gene transfer efficiency and cytotoxicity had to 
be investigated.  
Hydrophilic polyethylene glycol (PEG) has been used as part of polycation conjugates to 
enhance solubility and stability of polyplex formulations. In addition PEG may shield the 
surface charge, reducing undesired nonspecific interaction and cytotoxicity. The second aim 
of this study was to elucidate if the DMMAn-Mel concept is transferable to PEI-PEG and PLL-
PEG block copolymers. On basis of the PEG copolymers, conjugates containing the lytic 
peptides melittin, DMMAn-Mel and influenza peptide were synthesized and pDNA and siRNA 
delivery efficiencies had to be compared.   
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Conventional polyplex and lipoplex formulations are held together electrostatically. A weak 
point resides in the fact that other charged biomolecules can disrupt the complexes before 
they reach the site of action. Other research groups demonstrated that both serum and 
extracellular matrix can lead to vector disassembly [52;53]. They observed significant vector 
unpackaging of systemically injected PEI / pDNA polyplexes and dissociation of siRNA 
complexes in human serum. As the third aim of the thesis, to guarantee the association of 
the siRNA with the polycationic carrier, a synthetic method to covalently attach the siRNA 
had to be developed. Accordingly, the most promising noncovalent carrier for siRNA delivery 
as found in the second part of the thesis was covalently modified with siRNA. To enable 
release of the free siRNA in the cytosol a reducible disulfide bond was chosen as linkage. 
Release of the siRNA under physiological conditions had to be investigated by agarose gel 
electrophoresis studies and the gene silencing activity of the siRNA-conjugate had to be 
compared with the activity of a corresponding polyplex containing electrostatically complexed 
siRNA. 
 
  Material and methods  17 
 
2 Material and methods  
2.1 Chemicals and reagents 
Branched polyethylenimine (PEI; average MW = 25 kDa) and poly-L-lysine-hydrobromide 
(PLL, MW = 32000, degree of polymerization (DP) = 153 or PLL, MW = 55000, DP = 263) 
were obtained from Sigma-Aldrich (Munich, Germany).  
Succinimidyl 3-(2-pyridyldithio) propionate (SPDP), 2,3-dimethylmaleicanhydride (DMMAn) 
and succinicanhydride (Succ), 1,4-Dithiothreitol (DTT), Tris(2-carboxyethyl)phosphine 
(TCEP), ethidium bromide (EtBr) were obtained from Sigma-Aldrich. Succinimidyl propionate 
monomethoxy polyethylene glycol (SPA-mPEG, MW = 5000) was purchased from Fluka 
(Buchs, Switzerland). RNAse-free water, absolute ethanol, deuterium oxide (D2O) and 
dimethyl sulfoxide puriss. (DMSO) were purchased from Sigma-Aldrich. Water was used as 
purified, deionized water.  
Cysteine-modified melittin (Mel) was obtained from IRIS Biotech GmbH (Marktredwitz, 
Germany). Mel had the sequence CIGA VLKV LTTG LPAL ISWI KRKR QQ (all-(D) 
configuration), the C-terminal amino acid was introduced as carboxylic acid, the N-terminal 
amino acid as amine. All-(D) stereochemistry was used because it is nonimmunogenic while 
being as lytic as the natural peptide. Influenza peptide (INF7, sequence GLFE AIEG FIEN 
GWEG MIDG WYGC) was synthesized by Christian Plank, Institute of Experimental 
Oncology and Therapy Research, Technical University Munich. 
Plasmid pCMVLuc (Photinus pyralis luciferase under control of the CMV enhancer/promoter) 
was produced with the Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) according to the 
manufacturer recommendations. Ready to use siRNA duplexes were purchased from MWG-
Biotech (Ebersberg, Germany) namely, luciferase-siRNA: GL3 luciferase duplex: 5’-
CUUACGCUGAGUACUUCGA-3’; control-siRNA: non-specific control duplex IX with similar 
GC content as anti-luciferase-siRNA and Cy5-siRNA: Cy5-labeled GL3 luciferase duplex: 5’-
Cy5-CUUACGCUGAGUACUUCGA-3’. Thiol-modified GL3 and control siRNA were 
purchased from Dharmacon. Thiol-modified GL3 siRNA had the sequence 5'-thiol-
CUUACGCUGAGUACUUCGAdTdT-3' (sense). Thiol-modified control siRNA had the 
sequence 5’-thiol-AUGUAUUGGCCUGUAUUAGUU-3’ (Dharmacon’s non-targeting 
control#3).  
Cell culture media, antibiotics, and fetal calf serum were purchased from Invitrogen 
(Karlsruhe, Germany). Formulations for nucleic acid delivery were prepared in HBG (HEPES-
buffered glucose solution; 20 mM HEPES, 5% glucose, pH 7.4). Methylthiazolyldiphenyl-
tetrazolium bromide (MTT) was obtained from Sigma-Aldrich. Bafilomycin A1 was purchased 
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from Alexis Biochemicals (Lausen, Switzerland). Luciferase cell culture lysis buffer and D-
luciferin sodium salt were obtained from Promega (Mannheim, Germany).  
2.2 Conjugate synthesis 
2.2.1 Synthesis of 3-(2-pyridyldithio)propionate-modified PLL 
PLL (1 µmol; DP = 263) in 0.8 ml buffer (0.5 M NaCl, 20 mM HEPES, pH 7.4) was mixed with 
SPDP (20 µmol) dissolved in 200 µl dimethyl sulfoxide (DMSO). After 2 hours at room 
temperature (RT) PLL with pyridyldithiopropionate linkers (PLL-PDP) was purified by size 
exclusion chromatography (SEC) using an Äkta Basic high-performance liquid 
chromatography system (Amersham Biosciences, Freiburg, Germany) equipped with a 
Sephadex G25 superfine HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden) 
equilibrated in 0.5 M NaCl, 20 mM HEPES, pH 7.4; the flow rate was 0.5 ml/min. The void 
fractions containing PLL were pooled, aliquots were snap frozen in liquid nitrogen and stored 
at -80 °C. PLL content of the fractions was measured by trinitrobenzenesulfonic acid (TNBS) 
assay at 405 nm. The degree of modification with the dithiopyridine linker was determined 
spectrophotometrically at 343 nm by release of pyridine-2-thione: 10 µl of the sample was 
added to 140 µl water and blank absorbance at 343 nm was measured. Subsequently 5 µl of 
the reducing agent dithiothreitol (0.5 µmol, 77 µg; diluted in water) was added and release of 
pyridine-2-thione at 343 nm (molar absorptivity = 8080 M−1 cm−1) was measured. For the 
synthesis of PLL-Mel and PLL-DMMAn-Mel, the same PLL-PDP batch was used with a molar 
ratio of PLL/PDP of approximately 1 to 13. The average yield was 60 % (w/w percent) based 
on analysis of PLL .  
2.2.2 Synthesis of PEG-modified PEI and PLL 
PLL (1.25 µmol; DP = 153) in 2 ml buffer (0.5 M NaCl, 20 mM HEPES, pH 7.4) was mixed 
with mPEG-SPA (1.6 µmol, 8 mg) dissolved in 400 µl DMSO. After 2 h at RT the reaction 
mixture containing modified PLL (PLL-PEG) was loaded on a cation-exchange column 
(MacroPrep High S; HR 10/10, BioRad, München, Germany) and fractionated with a salt 
gradient from 0.6 to 3.0 M NaCl in 20 mM HEPES pH 7.4. The flow rate was 0.5 ml/min. The 
fractions containing PLL-PEG were pooled, dialyzed against water (MWCO of 6000 - 8000) 
and lyophilized. The degree of modification of PLL with PEG was determined by proton NMR 
(PLL / PEG = 1 / 1). The PLL content was measured by TNBS assay. The average yield 
(after dialysis and freeze-drying) was 63% based on analysis of PLL.     
Synthesis of PEI-PEG was carried out analogously as described for PEG-modified PLL, 
starting with 1,25 µmol PEI (31.3 mg) in 2 ml buffer  (0.5 M NaCl, 20 mM HEPES, pH 7.4) 
and mPEG-SPA (2.5 µmol, 12.5 mg) dissolved in 400 µl DMSO. The degree of modification 
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of PEI with PEG was determined by proton NMR (PEI/PEG = 1/1.5). Polycation content was 
measured by TNBS assay. The average yield (after dialysis and freeze-drying) was 70% 
based on analysis of PEI. 
2.2.3 Synthesis of 3-(2-pyridyldithio)propionate-modified PEI- and PLL-
PEG 
PLL-PEG (0.313 µmol, containing 6.45 mg PLL as free base) in 2 ml buffer (20 mM HEPES, 
pH 7.4) was mixed with SPDP (3.8 µmol, 1.19 mg) dissolved in 200 µl DMSO. After 2 h at RT 
PLL-PEG with pyridyldithio-propionate-linkers (PLL-PEG-PDP) was purified by gel filtration 
using an Äkta Basic HPLC System (Amersham Biosciences, Freiburg, Germany) equipped 
with a Sephadex G25 superfine HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden) 
equilibrated in 0.5 M NaCl, 20 mM HEPES, pH 7.4; the flow rate was 1 ml/min. The fractions 
containing PLL-PEG-PDP were pooled, aliquots were snap frozen in liquid nitrogen and 
stored at -80 °C. PLL content was measured by TNBS assay. The degree of modification 
with dithiopyridine linker was determined spectrophotometrically by release of pyridine-2-
thione as described in section 2.2.1. The PLL-PEG-PDP conjugate had a molar ratio of 
PLL/PEG/PDP of approximately 1/1/8. The average yield was 81% based on analysis of PLL.  
PEI-PEG-PDP was synthesized analogously as described for 3-(2-pyridyldithio)propionate-
modified PLL-PEG. PEI (0.313 µmol) in 1.84 ml buffer was mixed with SPDP (3.8 µmol, 1.19 
mg) dissolved in 200 µl DMSO. The PEI-conjugate had a molar ratio of PEI/PEG/PDP of 
approximately 1/1.5/11. The average yield was 74% based on analysis of PEI. 
2.2.4 Synthesis of PLL-Mel  
Melittin peptide (1.38 µmol) was dissolved in 400 µl of 0.5 M NaCl, 20 mM HEPES, pH 7.4, 
and mixed with 1000 µl PLL-PDP (71 nmol PLL with DP = 263, 0.93 µmol PDP) diluted in the 
same buffer under argon. After 3 h at RT released pyridine-2-thione  was measured at 343 
nm to determine the extent of the reaction. PLL-Mel conjugates were purified on the Äkta 
Basic HPLC system equipped with a Superdex 75 HR 10/30 column equilibrated in 0.5 M 
NaCl, 20 mM HEPES, pH 7.4. The flow rate was 0.5 ml/min. The void fractions containing 
PLL-Mel were pooled, aliquots were snap frozen in liquid nitrogen and stored at −80 °C. PLL 
content of the PLL-Mel conjugate was determined by TNBS assay. The concentration of 
melittin in the conjugates was measured by absorption at 280 nm (molar absorptivity of 
melittin = 5570 M−1 cm−1). The average yield was 66% based on analysis of PLL.  
2.2.5 Synthesis of DMMAn-Mel-modified PEI and PLL  
Mel peptide (1.38 µmol) was dissolved in 400 µl of 100 mM HEPES and 125 mM NaOH and 
mixed with 1000 µl ethanol containing 15.8 µmol DMMAn by rapid vortexing under argon for 
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0.5 h following concentration and purification via ultrafiltration (Vivascience, Vivaspin 2, 
MWCO 2000 HY). The acylated melittin was mixed with 1000 µl PLL-PDP (71 nmol PLL with 
DP = 263, 0.93 µmol PDP) diluted in 1 M guanidine hydrochloride, 0.5 M NaCl, 20 mM 
HEPES, pH 8. After 3 h at RT released pyridine-2-thione was measured at 343 nm to 
determine the extent of the reaction / the modification degree. Subsequent purification was 
carried out analogously to the PLL-Mel conjugate procedure as described above but using 
pH 8 buffers. The average yield was 64% based on analyis of PLL.  
PEI-DMMAn-Mel conjugate was synthesized analogously as described for PLL-DMMAn-Mel 
and had a molar ratio of approximately 1/8. The average yield was 54% based on analysis of 
PEI.  
2.2.6 Synthesis DMMAn-Mel-modified PEI- and PLL-PEG 
Mel peptide (1.38 µmol, 4 mg) was dissolved in 400µl of 100 mM HEPES and 125 mM NaOH 
and mixed with 1000 µl ethanol containing 15.8 µmol (2 mg) DMMAn under argon for 0.5 h 
following concentration and purification via ultrafiltration (Vivascience, Vivaspin 2, MWCO 
2000 HY). 1.38 µmol of the acylated melittin was mixed under argon with 1.06 ml PLL-PEG-
PDP (116 nmol PLL, 2.39 mg PLL, molar ratio of PLL/PEG/PDP of approximately 1/1/8) 
diluted in 2M guanidine hydrochloride, 0.5 M NaCl, 20 mM HEPES, pH 8. After 2 h at RT 
released pyridine-2-thione was measured at 343 nm to determine the extent of the reaction. 
The degree of modification was determined at 343 nm by release of pyridine-2-thione from 
residual PDP linkers after reduction with dithiothreitol. PLL-PEG-DMMAn-Mel conjugates 
were purified on the Äkta Basic HPLC System equipped with a Superdex 75 HR 10/30 
column (Pharmacia Biotech, Uppsala, Sweden) equilibrated in 0.5 M NaCl, 20 mM HEPES, 
pH 8. The flow rate was 0.5 ml/min. The void fractions containing PLL-PEG-DMMAn-Mel 
(molar ratio of PLL/PEG/DMMAn-Mel of approximately 1/1/8) were pooled and aliquots were 
snap frozen in liquid nitrogen and stored at − 80 °C. The PLL content of the conjugate was 
determined by TNBS assay. The average yield was 60% based on analysis of PLL.  
PEI-PEG-DMMAn-Mel conjugate was synthesized analogously, starting with 1.34 ml PEI-
PEG-PDP (83.6 nmol PEI, 2.1 mg PEI, molar ratios PEI/PEG/PDP of approximately 1/1.5/11) 
yielding in PEI-PEG-DMMAn-Mel conjugate with a molar ratio of PEI/PEG/DMMAn-Mel of 
approximately 1/1.5/8. The average yield was 56% based on analysis of PEI.  
2.2.7 Synthesis of INF-modified PEI- and PLL-PEG  
INF peptide (1.38 µmol) was dissolved in 400 µl of 0.5 M NaCl, 20 mM HEPES, pH 8 and 
mixed with 1060 µl PLL-PEG-PDP (116 nmol PLL, 2.39 mg PLL, molar ratio of 
PLL/PEG/PDP of approximately 1/1/8) diluted in the presence of 1.5 M guanidine 
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hydrochloride. After 2 h at RT released pyridine-2-thione was measured at 343 nm to 
determine the extent of the reaction. Following purification was carried out as described for 
DMMAn-Mel-modified PLL-PEG but using pH 7.4 buffers. The average yield was 43% based 
on analysis of PLL: 
PEI-PEG-INF conjugate was synthesized analogously starting with 1.34 ml PEI-PEG-PDP 
(83.6 nmol PEI, 2.1 mg PEI, molar ratio of PEI/PEG/PDP of approximately 1/1.5/11). The 
average yield was 50% based on analysis of PEI.  
2.2.8 Synthesis of Mel-modified PEI- and PLL-PEG 
Mel peptide (1.38 µmol, 4 mg) was dissolved in 400 µl of 0.5 M NaCl, 20 mM HEPES, pH 7.4 
and mixed with 1060 µl PLL-PEG-PDP (116 nmol PLL, 2,39 mg PLL, molar ratio of 
PLL/PEG/PDP of approximately 1/1/8) diluted in the same buffer under argon. After 2 h at RT 
released pyridine-2-thione was measured at 343 nm to determine the extent of the reaction 
and degree of modification. Subsequent purification was carried out as described for 
DMMAn-Mel-modified PLL-PEG but using pH 7.4 buffers. The average yield was 65% based 
on PLL. 
PEI-PEG-Mel conjugate was synthesized analogously starting with 1.34 ml PEI-PEG-PDP 
(83.6 nmol PEI, 2.1 mg PEI, molar ratio of PEI/PEG/PDP of approximately 1/1.5/11). The 
average yield was 78% based on analysis of PEI.  
2.2.9 Synthesis of succinic anhydride-melittin-modified PEI-PEG 
Mel peptide (1.38 µmol, 4 mg) was dissolved in 400µl of 100 mM HEPES and 125 mM NaOH 
and mixed with 1000µl ethanol containing 15.8 µmol (1.58 mg) succinicanhydride by rapid 
vortexing under argon for 0.5 h following concentration and purification via ultrafiltration 
(Vivascience, Vivaspin 2 HY, MWCO 2000). Subsequent coupling to PEI-PEG-PDP and 
purification of PEI-PEG-Succ-Mel was carried out analogously to the PLL-PEG-DMMAn-Mel 
conjugate procedure as described for DMMAn-Mel-modified PLL-PEG but using pH 7.4 
buffer for size exclusion chromatography. The yield was 80% based on analysis of PEI.  
2.2.10 Deprotection of thiol-modified siRNA 
Thiol-modified siRNA (with the sense strand modified at the 5’ end with a thiol-containing 
linker) was shipped with the thiol group in an oxidized (protected) form to prevent the 
formation of dimers. Prior to use, the thio groups of the modified siRNA were reduced into 
the free thiol form. 188 nmol of lyophilized GL3 luc siRNA was incubated for 1 hour at RT 
with 400 µl 0.05 M TCEP-solution under shaking. 150 µl 9.5 M ammonium acetate and 1.5 
ml ice cold ethanol was added and the solution was incubated for 20 minutes at -80 °C. 
Sequently the sample containing precipitated siRNA was centrifuged at 13400 rpm for 20 
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minutes. After pouring off the supernatant the sample was air dried for 15 minutes and the 
pellet reconstituted in 200 µl RNAse-free water. For complete removal of TCEP the 
precipitating procedure was repeated. siRNA quantification was carried out by obtaining an 
absorbance at 260 nm. The free thiol-groups were quantified by Ellman’s assay. This 
deprotection protocol allowed relatively high siRNA recovery rates with an approximate yield 
of  80%. Thiol-modified siRNA of the non-targeting control#3 sequence was prepared in 
analogous manner.  
2.2.11 Synthesis of PLL-PEG-DMMAn-Melittin-siRNA 
672 µl PLL-PEG-PDP (2.15 mg PLL; 0.84 µmol PDP) was mixed with 0.1 µmol thiol-siRNA 
(1.35 mg GL3 luc siRNA) and incubated for 1 h at RT under argon. Before adding siRNA, the 
solution was adjusted to 1.5 M NaCl. After 1 h at RT released pyridine-2-thione was 
measured at 343 nm to determine the extent of the reaction and degree of modification with 
siRNA. Subsequent DMMAn-Mel coupling was carried out analogously to DMMAn-Mel-
modified PLL-PEG (2.2.6) except high salt (1.5 M NaCl) was used instead of guanidine 
hydrochloride. The mixture containing the siRNA-conjugate was loaded onto a Superdex 75 
HR 10/30 column (eluent: 1M NaCl, 20 mM Hepes, pH 8.2; flow rate: 0.5 ml/min; 0.5 ml 
fractions collected). After purification the PLL-containing fractions were pooled and snap-
frozen in liquid nitrogen. The yield was 71% based on analysis of PLL. This conjugate was 
used for the in vitro transfection experiments.  
A second batch of PLL-PEG-DMMAn-Mel-siRNA conjugate containing GL3 luc siRNA was 
synthesized analogously, starting with 750 µl PLL-PEG-PDP (3.2 mg PLL; 1.05 µmol PDP). 
But after purification and pooling of the PLL-containing fractions, the siRNA-conjugate first 
desalted by dialysis.  The sample was placed in a 3 ml Slide-A-Lyzer cassette (MWCO 3500) 
and dialyzed for 4 hours at 4 °C against 9.5 liter HBG pH 8.2. After dialysis, the siRNA-
conjugate was snap-frozen in liquid nitrogen. The yield was 49% based on analysis of PLL.  
The conjugate containing Dharmacon’s non-targeting control #3 siRNA was 
synthesized analogously to the first batch of the GL3 luc siRNA – conjugate, starting with 250 
µl PLL-PEG-PDP (1.07 mg PLL; 0.35 µmol PDP). The yield was 58% based on analysis of 
PLL.   
2.2.12 Quantitative analysis of PEI and PLL (TNBS assay)  
The concentration of PEI and PLL was measured by TNBS assay. Standard PLL or PEI 
solutions and test solutions containing polycation were serially diluted in 0.1 M sodium 
tetraborate to a final volume of 100 µl using a 96 well plate, resulting in e.g. PLL hydrobromid 
concentrations of 10 to 60 µg/ml. To each well 2.5 µl of TNBS (75 nmol, 22 µg; diluted in 
water) was added. TNBS reacts with primary amino groups to form colored trinitrophenylated 
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derivatives. After 5 - 20 minutes incubation time at RT (depending on the strength of the 
developed colour) the absorption was measured at 405 nm using a microplate reader 
(Spectraflour Plus, Tecan Austria GmbH). 
2.2.13 Determination of PEG to polycation ratio  
1H NMR spectra were recorded on a Jeol JNMR-GX500 (500 MHz) spectrometer. Chemical 
shifts are reported in parts per million (ppm) and refer to the solvent as internal standard 
(D2O at 4.8 ppm). 3 mg of dialyzed and lyophylized material were dissolved in 1.2 ml D2O.   
PLL-PEG (Fig. 6): 1.26 – 1.82 (-CH2- ; PLL); 2.96 (-CH2-N-; PLL); 4.27 (-NCHR-COO-); 3.66 
(-CH2-CH2-O-; PEG). The content of PEG was calculated from the proton integrated values 
of PEG (-CH2-CH2-O-, 3.66 ppm) and the polylysine backbone protons (-NCHR-COO-, 4.27 
ppm) and from the molecular weight values of the polymers and PEG given by suppliers.  
 
Fig. 6: H-NMR spectra of PLL-PEG. Calculation of PLL to PEG5000 ratio: ppm 4.2 = 153.00 protons 
(1 PLL molecule, 153 lysines per polymer); ppm 3.8 = 499.54  1.1 PEG5000-molecules (453 protons 
per PEG polymer). PLL / PEG ~ 1/1   
 
PEI-PEG: The content of PEG was calculated (analogously to the PLL-PEG-conjugate) from 
the proton integrated values of PEG (-CH2-CH2-O-, 3.66 ppm) and the ethylenimine protons 
(-CH2-CH2-NH-, 2.5 – 3.1 ppm) and from the molecular weight values of the polymers and 
PEG given by suppliers. 
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2.2.14 Ellman’s assay 
This assay is a colorimetric reaction between Ellman's reagent (5,5'-dithiobis(2-nitrobenzoic 
acid), DTNB) and the free thiol groups. 0.4 mg DTNB dissolved in 1 ml of the corresponding 
Ellman´s buffer (0.2 M Na2HPO4 with 1 mM EDTA at pH 8.0) was used as stock solution. For 
VIS absorption measurement Ellman´s stock diluted 1:10 in Ellman´s buffer was taken as 
blank. Standard cystein solution and samples were serially diluted in Ellman’s buffer and 
10% (v/v) of the stock solution. After 20 minutes at 37 °C the solutions were measured at 412 
nm and concentration of the thiol group was calculated via the standard curve.  
2.3 Polyplex formation 
pDNA encoding luciferase was complexed with polycations at different ratios of polycation to 
pDNA in HBG at a pDNA concentration of 20 µg/ml during polyplex formation. In case of 
PLL, PLL and PLL-conjugates were mixed at different molar ratios of PLL epsilon-amino 
nitrogen to DNA phosphates (N/P ratio). For instance, DNA/PLL polyplexes at N/P 2 were 
prepared by mixing a solution of 2 µg of pDNA in 50 µl HBG with a solution of 2.66 µg PLL in 
50 µl HBG. For Tf-targeted polyplexes, polycations PLL (N/P = 1.7) / PLL-Tf (N/P = 0.3) were 
applied, for Tf-targeted and PEG-shielded polyplexes polycations PLL (N/P = 1.3) / PLL-Tf 
(N/P = 0.3) / PLL-PEG (N/P = 0.4) were applied.  pDNA was condensed with PEI or PEI-
conjugates at a molar ratio of PEI nitrogen to DNA phosphate (N/P ratio) of 6. Polyplexes 
were rapidly mixed by pipetting and allowed to stand for 20 - 30 min at RT before use. 
Formulations for siRNA delivery were prepared as follows: first 2 µg siRNA and adequate 
amounts of the PEI- or PLL-conjugates using various polycation / siRNA ratios (w/w) were 
diluted in separate tubes in HBG. Then, the polycation solution was added to the siRNA, 
mixed by pipetting up and down and incubated for 20 – 30 min at RT to form the siRNA 
polyplexes that were used for transfection experiments. 
2.4 Measurement of zeta-potential 
Zeta-potential of nucleic acid complexes was measured using a Malvern Zetasizer 3000 HS 
or a Zetasizer Nano series ZEN 3600 (Malvern Instruments, Worcestershire, UK). Polyplexes 
were formed at a nucleic acid concentration of 20 µg/ml in HBG and were allowed to stand 
for 20 – 30 min. For estimation of surface charge with Malvern Zeta Sizer Nano series, 
transfection complexes were diluted in 1 mM NaCl to give a final nucleic acid concentration 
of 10 µg/ml and zeta potential was measured. In case of Malvern Zetasizer 3000 HS 
complexes were diluted in 1 mM NaCl to give a final volume of 5 ml and a DNA concentration 
of 2 µg/ml. Average values were calculated with the data of 10 runs with standard deviation. 
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2.5 Measurement of particle size via dynamic light scattering (DLS) 
Particle size of nucleic acid complexes was measured by laser-light scattering using a 
Malvern Zetasizer 3000 HS or a Zetasizer Nano series ZEN 3600 (Malvern Instruments, 
Worcestershire, UK). Polyplexes were formed at a nucleic acid concentration of 20 µg/ml in 
HBG and were allowed to stand for 20 – 30 minutes. Prior to size measurement transfection 
complexes were diluted to give a final nucleic acid concentration of 10 µg/ml. 
2.6 Measurement of particle size via fluorescence correlation 
spectroscopy 
Fluorescence correlation spectroscopy (FCS) was employed to determine the size 
(hydrodynamic radius) of siRNA polyplexes. For FCS experiments siRNA labeled with Cy5 
was utilized. FCS detects spontaneous intensity fluctuations resulting from fluorescently 
labeled molecules diffusing through a highly focused laser illuminated volume within the 
sample. The size of this volume is fixed by the confocal detection optics and the excitation 
profile of the focused laser beam and characterized by calibration measurements against a 
standard of a known diffusion constant. The raw signal, the time dependent fluorescence 
intensity fluctuations, is time-autocorrelated to obtain dynamic information on the 
fluorescently labeled molecules. For free Brownian diffusion of one identical species of 
particles, the autocorrelation function is given by 
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Where N represents the number of particles in the illuminated volume and  
xyr
zS 0=  the 
structure parameter, the ratio of axial to radial dimensions of the focused laser beam which is 
a measure for the dimensions of the focal volume. The diffusion time τD of a particle through 
the illuminated focal volume with radius rxy is related to the translational diffusion 
coefficient D  by  
D
rxy
D 4
2
=τ     (2) 
Additional intensity fluctuations can occur resulting from intramolecular processes like 
transitions to triplet states. If these processes are well separated in the time domain the 
autocorrelation function can be written as 
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where Ttriplett denotes the triplett fraction and τtriplett  the characteristic triplett decay time. 
For fluorescently labeled spherical particles with dimensions smaller than the illuminated 
focal volume (R<<rxy) diffusing through a homogeneous solvent consisting of small 
molecules (R>>rsolvent) the hydrodynamic radius RH can be calculated from the Stokes-
Einstein relation 
D
Tk
R BH
piη6
=  (4) 
D denotes the translational diffusion coefficient of the particle, kB the Boltzmann constant, T 
the temperature and η the solvent viscosity.  
FCS experiments were performed using a commercially available FCS setup (Carl Zeiss, 
Jena, Germany), consisting of the Confocor 2 module and an Axiovert 200 inverted 
microscope equipped with a Zeiss C-Apochromat 40x, N.A. 1.2 water immersion objective. 
The illumination source was a HeNe Laser (633nm, 5mW) with emission passed through a 
650nm long-pass before detection. All FCS measurements were performed at RT. Samples 
were pipeted directly into eight-well Lab-Tek chambers (Nalge Nunc International, Rochester, 
NY). Determination of the focal volume was established via calibration against an aqueous 
solution of 10 nM Cy5 before each data acquisition. For each sample 10 measurements with 
sampling time of 30s were performed. The measured autocorrelation curves were fitted 
(Zeiss ConfoCor2 software package) with equation (3),  the resulting diffusion time τD was 
used to calculate the hydrodynamic radius RH of the siRNA polyplexes via equations (2) and 
(4).  
2.7 Ethidium bromide exclusion assay 
The binding strength of the conjugates to siRNA was compared via EtBr exclusion. The 
fluorescence of EtBr is significantly enhanced by nucleic acid intercalation. When a 
polycation binds to the nucleic acid, intercalated EtBr is displaced, and a reduction of 
fluorescence can be noticed. The fluorescence of a 20 µg/ml solution of nucleic acid 
containing 400 ng/ml of EtBr in HBG was first measured (ex 510 nm, em 590 nm, slit width = 
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10 nm, Varian Cary Eclipse fluorescence spectrophotometer) and fluorescence was set to 
100%. Aliquots of the conjugates were added stepwise to the nucleic acid EtBr solution and 
the decrease of fluorescence was measured indication interaction of the conjugate with the 
nucleic acid.  
2.8 Agarose gel electrophoresis 
A 2.5% agarose gel was prepared by dissolving 1 g agarose (Sigma-Aldrich, Taufkirchen, 
Germany) in 40 g TBE buffer (trizma base 10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g ad 
1000 ml Millipore water) and boiling everything up to 100 °C. After cooling down to about 50 
°C the agarose gel was casted in the electrophoresis unit. Sample preparations containing 
500 ng siRNA and loading buffer (12 ml glycerine, 2.4 ml 0.5 M EDTA, 5.6 ml H2O, 0.04 g 
xylenecyanole) were placed into the sample pockets. For reduction of disulfides samples 
were treated with TCEP or glutathione. To inhibit electrostatic interactions between the 
nucleic acid and the polycations samples were treated with heparin.  Electrophoresis was 
performed at 80 V for 40 minutes. Alternatively a 2.5% agarose gel with 120 g TBE buffer 
was prepared and settings were adapted.   
2.9 Erythrocyte leakage assay 
Human erythrocytes were isolated from fresh, citratetreated blood and washed in phosphate-
buffered saline (PBS) by four centrifugation cycles, each at 800 g for 10 min at 4 °C. The 
erythrocyte pellet was diluted 10-fold in 150 mM NaCl. Melittin, DMMAn-melittin and PLL-
melittin conjugates were serially diluted in 90 µl buffer (HBS, pH 7.4) using a V-bottomed 96-
well plate, resulting in melittin concentrations of 0.25 - 16 µM. For 100% lysis, control wells 
contained buffer with 1% Triton X-100. A volume of 10 µl of erythrocyte suspension was 
added to each well and the plates were incubated at 37 °C for 30 min under constant 
shaking. After centrifugation at 300 g for 10 min, 60 µl supernatant were analyzed for 
hemoglobin release at 450 nm using a microplate plate reader (Spectrafluor Plus, Tecan 
Austria GmbH, Grödig, Austria). 
2.10 Cell culture 
Cell culture media, antibiotics and foetal bovine serum (FBS) were purchased from Invitrogen 
GmbH (Karlsruhe, Germany). Cultured cells were grown at 37 °C in 5% CO2 humidified 
atmosphere. Neuro2A murine neuroblastoma cells (ATCC CCL-131) and Neuro2A-eGFPLuc 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 1 g/l glucose) containing 
10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine. HUH-7 
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hepatocellular carcinoma cells (JCRB 0403; Tokyo, Japan) and HUH-7-eGFPLuc cells were 
cultured in DMEM high glucose / F12 (1/1) containing 10% FBS, 100 U/ml penicillin, 100 
µg/ml streptomycin and 2 mM glutamine 
2.11 Luciferase gene silencing  
All experiments were performed in stably transfected Neuro2A-eGFPLuc cells. Cells were 
seeded in 96-well plates (TPP, Trasadingen, Switzerland) using 5000 cells per well 24 h prior 
to transfection. Transfection complexes containing siRNA were then added to cells in 100 µl 
culture medium containing 10% serum, 100 U/ml penicillin and 100 µg/ml streptomycin (final 
siRNA-concentration 367 nmol/l). 48 h after initial transfection medium was removed and 
cells were lysed in 50 µl Promega cell lysis solution to measure the gene expression as 
described below. Transfections were also performed with a non-specific control siRNA to 
distinguish between specific gene silencing and unspecific knockdown of protein expression 
due to carrier toxicity. Qualitative judgement on the toxicity of the conjugates was made by 
diminution in luciferase expression upon delivery of the non-specific control siRNA compared 
to the luciferase expression from the same number of cells that were not exposed to the 
carrier. Data were generated by Alexander Philipp as part of his PhD thesis (in preparation). 
2.12 Luciferase reporter gene expression 
Cells were plated in 96 well plates at a density of 10000 cells (Neuro2A or HUH7) per well 24 
h prior to transfection. The polyplexes with 200 ng of pDNA (pCMVLuc) were added to the 
cells in 100 µl culture medium containing 10% serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin. For investigating the effect of endosomal acidification the transfection medium 
was supplemented with 200 nM of the inhibitor bafilomycin A1 (Alexis Biochemicals 
Corporation). The transfection medium was replaced after 3 h by 100 µl fresh cell culture 
medium. 24 h after initial transfection medium was removed and cells were lysed in 50µl 
Promega cell lysis solution to measure the gene expression. Luciferase activity was 
measured using a Lumat LB9507 instrument (Berthold, Bad Wildbad, Germany). Luciferase 
light units were recorded from an 20µl aliquot of the cell lysate with 10 s integration time after 
automatic injection of freshly prepared luciferin using the luciferase assay system (Promega, 
Mannheim, Germany). Transfection efficiency was evaluated as relative light units (RLU) per 
number of seeded cells. Two ng of recombinant luciferase (Promega, Mannheim, Germany) 
corresponded to 107 light units. 
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2.13 Cell viability assay (MTT assay) 
Metabolic activity of cells was determined using a methylthiazoletetrazolium (MTT) / thiazolyl 
blue assay as follows: 10 µl of a 5 mg/ml solution of MTT in sterile PBS buffer was added to 
each well of the 96 well plate. After incubation for 2 h at 37 °C, the medium was removed 
and cells were frozen for 2 hours (-80 °C). 100 µl of DMSO was added and samples were 
further incubated at 37 °C for 30 min under constant shaking. Optical absorbance was 
measured at 590 nm (reference wavelength 630 nm) using a microplate reader (Spectrafluor 
Plus) and cell viability was expressed as a percent relative to buffer (HBG)-treated control 
cells.  
2.14 Cytotoxicity assay (LDH release assay) 
Cells were seeded in 96-well plates and treated after 24 h with different amounts of 
conjugates ranging from from 2.4 to 14.8 µg/ml. Cytotoxicity was determined after 30 min 
using the lactate dehydrogenase (LDH) release assay (Promega, CytoTox 96 nonradioactive 
cytotoxicity assay) according to the manufacturer’s instructions. 
2.15 Transmission light microscopy   
Transmission light microscopy of living cells was performed after 1 hour of conjugate 
treatment using an Axiovert 200 microscope (Carl Zeiss, Jena, Germany) equipped with a 
Sony DSC-S75 digital camera (Sony Corporation, Tokyo, Japan). Light was collected 
through a 32 x 0.25 NA objective (Zeiss), and images were captured using phase contrast. 
2.16 Cy5 labeling of pDNA 
Plasmid pCMVLuc was labeled with the fluorophore Cy5 using the Label IT kits (MIRUS, 
Madison, WI) following the manufacturer´s instructions. 20 µg of pDNA were diluted with 1 x 
Buffer A to a final volume of 195 µl. After addition of 5 µl reconstituted Label IT reagent, the 
reaction mixture was incubated for 3 h at 37 °C. To precipitate labeled DNA, 550 µl of ice-
cold ethanol and 22 µl of 3 M sodium acetate were added. The solution was then mixed and 
placed at - 20 °C overnight. Subsequent centrifugation at 16000g for 60 min (4 °C) allowed 
removal of unreacted label in the supernatant. The pellet was gently washed with ice-cold 70 
% ethanol, centrifuged again and all traces of ethanol were removed. Labeled DNA was 
allowed to dry for 5 min and finally resuspended in sterile HBG. Cy5 (ε 650nm = 250000 
l•mol-1•cm-1) content was measured by absorption at 650 nm. DNA was quantified by 
measuring the absorbance at 260 nm with the ratio of 260 nm / 280 nm serving as an index 
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for DNA purity (≥1.8; ≤1.9). On average, one dye molecule was bound per 100 bp, 
approximately. 
2.17 Flow cytometric analysis of cellular polyplex internalization 
Neuro2A cells were seeded in 12 well plates (TPP, Trasadingen, Switzerland) at a density of 
80000 cells per well 24 h prior to transfection. PLL polyplexes containing Cy5-labeled pDNA 
(20 % labeled pDNA / 80% unmodified pDNA) were added to the cells at a concentration of 
1.5 µg DNA per well in 1 ml fresh culture medium. Polyplexes were generated at a N/P ratio 
of 2 in HBG. After 3 h incubation at 37° C medium was removed, cells were washed with cold 
PBS, treated with trypsin / EDTA solution (Invitrogen GmbH, Karlsruhe, Germany), 
resuspended in cold PBS and kept on ice until cell uptake of polyplexes was assayed using a 
Cyan MLE flow cytometer (DakoCytomation, Copenhagen, Denmark). Before measurement 
propidium iodide was added to distinguish dead, permeable cells from undamaged, live cells.  
Dead cells show fluorescence caused by binding of the dye to cellular DNA and RNA that is 
higher staining than that of intact cells. The fluorophore Cy5 was excited at 635 nm and 
emission was detected at and 665 ± 20 nm. Data acquisition was performed in linear mode 
and data were analyzed in logarithmic mode. To discriminate between viable and dead cells, 
cells were appropriately gated by forward versus sideward scatter; to exclude doublets cells 
were gated by forward scatter versus pulse width, and 2 x 104 gated events per sample were 
collected. Experiments were performed in duplicates. 
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3 Results 
3.1 A dimethylmaleic acid–melittin-polylysine conjugate for pDNA 
delivery  
3.1.1 Design and synthesis of the DMMAn-modified PLL conjugate  
Aim of the work was to create an endosomolytic PLL-based non-viral nucleic acid carrier. 
PLL belongs to the class of synthetic amino acid polycations which can be ionically 
complexed to nucleic acids. Due to the natural amino acid backbone it is easily metabolized 
and thus should possess a low long-term toxicity. Endosomolytic properties and transfection 
activity however are very low. To overcome this limitation, melittin was grafted onto the 
polycation. DMMAn modification of melittin was carried out to mask the lytic activity in the 
extracellular environment (and thus reduce acute toxicity of the carrier). Endosomal 
acidification is exploited to trigger the lytic activity in the intracellular environment. Hence a 
relatively low cytotoxicity and high gene transfer efficiency should characterize the pH-
responsive gene carrier. The design is shown schematically in Scheme 1.  
 
 
 
 
 
 
 
 
 
 
 
 
   
                                  
 
 
Scheme 1: Design of the bioresponsive melittin conjugate 
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For the synthesis non-immunogenic all-(D)-melittin was used. All-(D)- and all-(L)-melittin 
have the same hemolytic and antibacterial activities [133;134]. It was shown that gene 
transfer activity of melittin-PEI polyplexes does not depend on the enantiomeric configuration 
of the attached peptide [103]. In order to synthesize the endosomolytic gene carrier, 
DMMAn-Mel was conjugated to PDP-modified PLL by disulfide bond formation. DMMAn-Mel 
was produced using an excess of DMMAn. Excess of DMMAn in the reaction mixture which 
could cause undesired acylation of primary amines on PLL during the coupling procedure 
was removed by filtration through a Vivaspin ultrafiltration unit. Coupling with PLL-PDP was 
carried out in the presence of 1 M guanidine hydrochloride. Guanidine hydrochloride 
prevents aggregation of the negatively charged DMMAn-Mel and the polycation before 
coupling. Purification was performed by SEC with the column equilibrated at pH 8 to avoid 
acidic cleavage of DMMAn. Resulting conjugates had 7 to 10 molecules peptide per PLL. A 
schematic illustration of the synthesis is shown in Fig. 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Synthesis of PLL-DMMAn-Mel conjugate. The primary amino groups of PLL react with the 
succinimidyl group of SPDP resulting in 3-(2-pyridyldithio)propionate modified PLL. In a second 
synthesis step the free sulfhydryl groups of cysteine at the N-terminus of DMMAn-melittin react with 
dithiopyridine to the desired PLL-DMMAn-Mel conjugate. 
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3.1.2 pH-dependent lytic activity 
To evaluate the membrane destabilizing activity of unmodified melittin in comparison with 
DMMAn-modified melittin, lytic activites of the peptides were investigated in an erythrocyte 
leakage assay (Fig. 8). Erythrocytes were incubated with the peptides in HBS, pH 7.4 
(extracellular pH) or citrate buffer, pH 5 (endosomal pH) for 30 minutes at 37 °C. The free 
peptide exposed high lytic activity (> 93% of hemoglobin release) at neutral pH at 
concentrations of 4.5 µM and above which is consistent with previously published work [103]. 
In contrast, DMMAn-Mel showed relatively low lytic activity at neutral pH (< 20%). However, 
at pH 5 lytic activity of DMMAn-Mel increased and reached comparable levels like 
unmodified melittin (50 – 60% of hemoglobin release).      
 
 
 
 
 
 
 
 
 
Fig. 8: Erythrocyte leakage assay. Erythrocyte lysis induced by free melittin and DMMAn-Melittin at 
neutral and endosomal pH. Washed human erythrocytes were incubated with melittin and DMMAn-
melittin peptides at different peptide concentrations.  
 
The lytic activity of the PLL-Mel conjugate was similar to free melittin, suggesting that 
covalent attachment of PLL to melittin did not significantly affect the lytic activity (Fig. 9). 
PLL-DMMAn-Mel conjugate showed relatively low lytic activity at neutral pH (< 20%). After 
acidic preincubation at pH 5, lytic activity was enhanced (80% hemoglobin release). At 
neutral pH, a longterm study (2.5 h preincubation of PLL-DMMAn-Mel at 37 °C and pH 7.4) 
revealed that lytic activity increased, but is still lower compared to the unmodified PLL-Mel 
conjugate (approximately 50% hemoglobin release at highest concentration). 
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Fig. 9: Erythrocyte leakage assay. Erythrocyte lysis induced by melittin conjugates at pH 7.4. 
Washed human erythrocytes were incubated with increasing conjugate concentrations. The conjugate 
PLL-DMMAn-Mel was preincubated at pH 5 for 30 minutes at room temperature (open squares) 
before performing the assay.  
3.1.3 Gene transfer activity 
Reporter gene expression (luciferase activity) and cellular toxicity were evaluated in Neuro2A 
cells after the application of different polyplex formulations. For transfection experiments, 
polyplexes were generated in HBG at N/P ratios of 1 to 4 (Fig. 10a).  While PLL mediated 
only low gene transfer, PLL-Mel showed the highest gene transfer activity at N/P 2. At higher 
N/P ratios the gene transfer activity of PLL-Mel decreased. In contrast PLL-DMMAn-Mel 
mediated high gene transfer activity at all N/P ratios (Fig. 10a). In parallel a cytotoxicity 
assay was performed to detect the amount of LDH in the medium which was released after 3 
h of transfection time (Fig. 10b). While at N/P ratios of 1 and 2 no LDH was detectable in the 
case of any polyplex formulation, at higher N/P ratios the PLL and PLL-Mel but not PLL-
DMMAn-Mel polyplexes induced LDH release up to 15% and 25% LDH release (100% refers 
to completely lysed cells). A higher toxicity of the PLL and PLL-Mel polyplex formulations as 
compared to PLL-DMMAn-Mel also explains the decreasing luciferase expression at higher 
N/P ratios.  
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Fig. 10: Gene transfer with PLL, PLL-Mel or PLL-DMMAn-Mel polyplexes. Neuro2A cells were 
treated with pCMVLuc polyplexes at different N/P ratios (1 to 4). Luciferase gene expressions at 24 h 
after transfection are shown in (a). White bars indicate PLL, black bars PLL-Mel and grey bars PLL-
DMMAn-Mel. Corresponding LDH-release values are shown in (b). 
 
 
To investigate the effect of endosomal acidification on the gene transfer activity of the 
conjugates 200 nM bafilomycin A1, an inhibitor of vacuolar ATPase endosome pumps, was 
included in the transfection medium (Fig. 11). As expected, the efficiency of standard PEI 
polyplexes was about 7-fold reduced. Bafilomycin A1 did not alter gene transfer of PLL 
polyplexes, but 3- and 8-fold enhanced gene transfer activity of the PLL-Mel conjugate at N/P 
ratios of 2 and 1, respectively. Gene transfer by PLL-DMMAn-Mel was slightly (up to approx. 
2-fold) reduced by the treatment.  
 
 
 
N/P 
PLL PLL-Mel PLL-DMMAn-Mel 
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Fig. 11: Effect of bafilomycin A1 on gene transfer. Luciferase gene expression after transfection of 
Neuro2A cells with PLL, PLL-Mel or PLL-DMMAn-Mel polyplexes in medium supplemented with 200 
nM of the inhibitor bafilomycin A1.  Medium was replaced by fresh medium after 3 hours, luciferase 
expression was determined after 24 h. 
 
The incorporation of targeting ligands and shielding domains into polyplexes is advantageous 
in terms of polyplex stability and systemic administration. Hence polyplexes containing 
transferrin (Tf) as targeting ligand and polyethylene glycol (PEG 20k) as shielding domain 
were generated at an N/P ratio of 2. Additional polyplexes containing PLL-PEG with pH-
sensitive hydrazone PEG-linkers (PLL-HZN-PEG) were generated and compared with regard 
to reporter gene transfer. PLL-PEG and PLL-HZN-PEG were synthesized as described in 
[120]. In all polyplex compositions, linkage of Mel or DMMAn-Mel to PLL enhanced luciferase 
expression between 85-fold and more than 1000-fold (Fig. 12). Incorporation of PEG, either 
stably- or pH-reversibly-linked, into polyplexes had no considerable negative effect on 
transfection efficiency.  
In summary, attachment of DMMAn-Mel greatly enhanced gene transfer efficiency of PLL, 
which for itself only revealed poor delivery activity. 
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Fig. 12: Luciferase gene expression with different polyplex formulations. Luciferase gene 
expression after transfection of Neuro2A cells with PLL, PLL-Mel or PLL-DMMAn-Mel polyplexes 
generated at N/P 2. Black bars indicate 100 (molar) % indicated conjugate, white bars indicate 85% 
conjugate and 15% PLL-Tf, grey bars indicate 65% conjugate, 15% PLL-Tf and 20% PLL-PEG, striped 
bars indicate 65% conjugate, 15% PLL-Tf and 20% PLL-HZN-PEG.  
 
3.1.4 Biophysical characterization 
Determinaton of particle size is important in two kinds of aspects. On the one hand small 
polyplexes (< 500 nm) are desirable for in vivo administration because large aggregates 
could trigger acute toxicity after systemic administration. On the other hand information about 
the particle size is necessary to properly judge the in vitro transfection experiments in well 
plates: large aggregates can sedimentate on the cell surface, in contrast limited transport of 
small particles to the cell surfaces could lead to decreased transfection efficiency. Thus 
differences in transfection efficiency between varying polyplex formulations might be not only 
due to to the composition (e.g. incorporation of targeting ligands or lytic agent) but also due 
to resulting different sizes of the polyplexes. The ratios (% w/w) are based on the amount of 
PLL present in the PEG or transferrin conjugates or the PLL stock solutions. The PLL 
conjugate mixture was mixed with pDNA diluted in HBG at an N/P ratio of 2 and a final pDNA 
concentration of 20 µg/ml. Particles were analyzed by using a Malvern Zetasizer 3000 HS 
(Table 1). 
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Polyplex formulations  Particle size [nm] Zeta potential [mV] 
PLL   74 +/- 8 22,6 +/- 5,8 
PLL-Mel  133 +/- 38 16,51 +/- 1,1 
PLL-DMMAn-Mel 211 +/- 29 17,21 +/- 1,0 
PLL 85% / 15%Tf  95 +/- 18 9,90 +/- 1,5 
PLL-Mel 85% / 15%Tf  109 +/- 29 13,34 +/- 0,6 
PLL-DMMAn-Mel 85% / 15% Tf 233 +/- 21 13,8 +/- 0,7 
PLL 65% / 15%Tf / 20%PEG 158 +/- 79 3,7 +/- 1,3 
PLL-Mel 65% / 15%Tf / 20%PEG 144 +/- 25 12,7 +/- 0,9 
PLL-DMMAn-Mel 65% / 15%Tf / 20%PEG  178 +/- 38 3,7 +/- 0,6 
 
Table 1: Particle size and zeta potential of polyplexes 
pDNA complexes were prepared in HBG at a N/P ratio of 2. pDNA concentration during polyplex 
mixing was 20 µg/ml. Polyplexes were allowed to stand for 20 – 30 minutes before measurement.   
 
The preparation of polyplexes under salt-free conditions resulted in overall small nanosized 
polyplexes. In general DMMAn-Mel containing polyplexes were slightly larger in size 
compared with their PLL- and PLL-Mel analogs. Incorporation of transferrin lowered the zeta-
potential. To achieve effective shielding incorporation of PEG (MW 20000) was necessary. In 
case of PLL-Mel application of the PEG-conjugate only resulted in partial shielding (+ 12.7 
mV) of the polyplex.  
The binding affinity of the conjugates to pDNA was evaluated by a competitive displacement 
assay using fluorescent EtBr. PLL showed an efficient DNA condensation at N/P ratio of 1. In 
the case of PLL-Mel and PLL-DMMAn-Mel conjugates higher amounts of polymer were 
necessary to achieve complete reduction of EtBr fluorescence (approx. N/P 2) (Fig. 13). 
 
 
 
 
 
 
 
 
 
Fig. 13: pDNA binding of PLL, PLL-Mel and PLL-DMMAn-Mel conjugates. Complexes were 
formed in the presence of EtBr in HBG and inhibition of EtBr/DNA fluorescence was monitored.  
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3.1.5 Cellular toxicity  
Toxicity of conjugates is of major interest and displays a limiting issue for application of 
polyplexes. To evaluate the differences in toxicity of PLL, PLL-Mel and PLL-DMMAn-Mel, 
relative metabolic activity of Neuro2A cells was determined after treatment with (free) 
conjugates. 3 hours after treatment, polymer containing medium was replaced by fresh 
medium and metabolic activity was determined after 24 hours. PLL and PLL-Mel reduced the 
metabolic activity of the cells to 15%, whereas, even for the highest concentration of PLL-
DMMAn, almost 50% of metabolic activity remained. No significant differences were found 
between PLL and PLL-Mel (Fig. 14). However 1 hour after initial treatment differences in cell 
morphology between PLL- and PLL-Mel-treated cells could be detected by transmission light 
microscopy (Fig. 15, PLL-concentration 4.8 µg/ml). In contrast to PLL- and PLL-DMMAn-Mel-
treated cells, PLL-Mel showed changes in cell morpology. Treatment with PLL-concentration 
of 23.8 µg/ml led to changes in cell morphology in case of PLL and PLL-Mel; PLL-DMMAn-
Mel-treated cells were not affected in a large extent. Cells were also assayed for metabolic 
activity already after 1 hour of conjugate treatment (data not shown), but PLL- and PLL-Mel 
displayed a similar toxicity profile in contrast to the observed visible changes is cell 
morphology. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: Cell viability of Neuro2A cells after conjugate treatment. Neuro2A cells were treated with 
indicated concentrations of PLL, PLL-Mel and PLL-DMMAn-Mel conjugates. Polymer-containing 
medium was replaced by fresh medium after 3 hours and metabolic activity was determined by MTT 
assay after 24 h.  
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Fig. 15: Transmission light images of Neuro2A cells after conjugate treatment. Pictures were 
taken 1 hour after initial conjugate treatment (PLL-concentrations: 4.8 µg/ml and 23.8 µg/ml) 
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Hence toxicity was further investigated by an LDH release assay. While the MTT assay 
technically spoken measures the activity of mitochondrial enzymes that reduce MTT to 
formazon, an LDH release indicates membrane damage and / or cell death. The normal 
plasma membrane is impermeable to cytosolic LDH, but damage to the cell membrane 
results in a change in the membrane permeability and subsequent leakage of LDH into the 
extracellular fluid. As illustrated in Fig. 16, the amount of released LDH increased with the 
increase in polymer concentration. The least LDH was released by PLL-DMMAn-Mel, 
whereas PLL-Mel induced the most LDH release, which supports the microscopy data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Polymer-induced lactate dehydrogenase release. Neuro2A cells were treated with 
indicated concentrations of PLL, PLL-Mel and PLL-DMMAn-Mel conjugates. After 0.5 h incubation 
time the amount of released LDH was determined.  
 
 
To exclude the possibility that all toxic effects are due to PLL and not melittin, a cytotoxicity 
assay (LDH-release) with melittin alone and PLL alone was performed. The corresponding 
amounts of melittin and PLL which are present in the PLL-Mel conjugate were compared at 
different concentrations (e.g. PLL at 2.4 µg/ml was compared with melittin 1.25 µg/µl). At the 
concentration range tested (PLL: 2.4 µg/ml – 19 µg/ml) both PLL and melittin exhibited a 
similar toxicity and induced LDH-release up to 60% (Fig. 17). As expected, melittin 
contributes to the toxicity of the PLL-Mel conjugate.  
Taken together, attachment of unmodified melittin increased toxicity of the polymer whereas 
modification with DMMAn-Mel reduced in vitro cytotoxicity.   
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Fig. 17: Cytotoxicity (LDH-release) induced by melittin and PLL on Neuro2A cells. 
Corresponding amounts of melittin and PLL which are present in the PLL-Mel conjugate were 
compared at different concentrations. 
3.2 PEGylated endosomolytic conjugates for pDNA and siRNA 
delivery 
3.2.1 Design and synthesis of the conjugates  
Currently polyethylenimines / oligoethylenimine-derived polymers are the most frequently 
used polycations for nucleic acid delivery [33]. Also in our workgroup novel ethylenimine-
based carriers have been developed, including biodegradable polymers and 
pseudodendrimers [130;135-137]. Accordingly, the next logical step was to transfer the 
promising DMMAn-Mel strategy from PLL to a PEI-based system. Hence branched PEI (25 
kDa) was chosen as backbone for modification with DMMAn-Mel. The synthesis was carried 
out analogously to PLL-DMMAn-Mel, after SPDP-modification of PEI, DMMAn-Mel was 
coupled via disulfide bond formation. Released pyridine-2-thione was measured at 343 nm to 
determine the DMMAn-Mel modification degree. Purification of the conjugate was carried out 
by SEC using a Superdex 75 HR 10/30 column (elution buffer: 0.5 M NaCl, 20mM Hepes, pH 
8) and yielded in a PEI-DMMAn-Mel conjugate with a molar ratio of approximately 1 PEI to 8 
DMMAn-Mel. The erythrocyte leakage assay showed the desired pH-dependent lytic activity 
similar to PLL-DMMAn-Mel (data not shown). However it was not possible to generate small 
nanosized nucleic acid polyplexes with PEI-DMMAn-Mel. Modification of PEI with the 
negatively charged DMMAn-Mel peptide induced polymer collapse and polyplex aggregation 
(> 1µm). In contrast modification of PEI with the unmodified positively charged melittin could 
be accomplished without problem [101]. As described above (section 3.1.4.) large particles 
are not favored in terms of systemic in vivo delivery and represent a serious exclusion 
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criterion for the development of carriers. To overcome this drawback PEI was first modified 
with monofunctional succinimidyl propionate polyethylene glycol (MW 5000). Size exclusion 
chromatography (Sephadex G25 superfine, Superdex 75, Superdex 200) and dialysis 
against a MWCO 6000 – 8000 membrane were not suitable to remove uncoupled PEG-
reagent from the mixture, thus the conjugate was purified by cation exchange 
chromatography. After PEGylation, the conjugate was modified with SPDP and sequently 
DMMAn-Mel was coupled via the terminal cysteine residue. This prePEGylation-strategy 
allowed the formation of soluble conjugates and the formation of nanosized polyplexes. 
Encouraged from this result, the negatively charged influenza peptide (INF) also was coupled 
to PEI-PEG.  
Finally four different peptide-conjugates were synthesized based on PEI: PEI-PEG-Mel, PEI-
PEG-DMMAn-Mel, PEI-PEG-INF and PEI-PEG-Succ-Mel. For synthesis of the conjugates,  
PEI-PEG with a molar ratio of 1:1.5 (PEI:PEG) was used. Measurement of released pyridine-
2-thione revealed that 7 to 11 peptides were coupled to PEI-PEG. After reaction of the 
peptides with PEI-PEG-PDP, unbound peptides and released pyridine-2-thione were 
removed by SEC using a Superdex 75 HR 10/30 column. In case of acid-sensitive PEI-PEG-
DMMAn-Mel, the elution buffer was adjusted to pH 8.2. Succ-Mel represents a negative 
control peptide were melittin’s lytic activity is irreversibly inhibited by stable modification of 
the primary amino groups with succinicanhydride (analogously to the DMMAn-modification of 
melittin).  
PEI has been considered the gold standard for gene carriers because of the relatively high 
transfection efficiency. However, if the focus is laid on in vivo application, PEI has the 
disadvantage of not being biodegradable. Therefore analog conjugates were synthesized 
with a PLL backbone (MW 32000, as hydrobromide), resulting in PLL-PEG-Mel, PLL-PEG-
DMMAn-Mel, and PLL-PEG-INF. PLL due to its peptide linkages represents a biodegradable 
polycation. The synthesis route of the PEI-PEG-peptides was adopted for the PLL-based 
conjugates. Cation exchange chomatograpy was used to remove free PEG from the PLL-
PEG containing synthesis mixture. PLL-PEG-PDP with a molar ratio of 1:1:8 (PLL:PEG:PDP) 
was modified with peptides yielding in peptide conjugates with approximately 6 to 8 peptides 
coupled to 1 PLL.         
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A schematic structure of all conjugates is shown in Scheme 2.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Schematic structure of the PEGylated endosomolytic conjugates 
 
Because modification of PLL with DMMAn-Mel had an effect on the cytotoxicity of the 
polymer, the toxicity of the free PEI-PEG-peptide conjugates was investigated with an LDH-
release cytotoxicity assay (Fig. 18).  Modification with DMMAn-Mel lowered the acute toxicity 
of PEI-PEG, in contrast an increased cytotoxicity was observed when unmodified melittin 
was attached.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: LDH-release induced by PEI-PEG-conjugates on Neuro2a cells. Neuro2A cells were 
treated with indicated concentrations of PEI, PEI-PEG, PEI-PEG-Mel and PEI-PEG-DMMAn-Mel 
conjugates. After 0.5 h incubation time the amount of released LDH was determined.  
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3.2.2 pDNA-delivery 
3.2.2.1 PEI-PEG-conjugates 
First of all the binding strength of the synthesized PEI-conjugates to pDNA was compared via 
EtBr exclusion assay. Modification with negatively charged DMMAn-Mel could result in an 
decreased pDNA binding ability. But except for modification with influenza peptide the effects 
of peptide-modification on the pDNA-binding capability were negligible. At an N/P ratio of 3 
sufficient pDNA-binding was observed (Fig. 19). 
As previously mentioned, DMMAn-Mel modification of PEI without prePEGylation resulted in 
polymer collapse and the formation of large pDNA-polyplexes (> 1 µm). Thus dynamic light 
scattering measurements were carried out to determine the size and zeta-potential of the 
PEI-conjugate / pDNA-complexes (Table 2). In general the complexes containing peptide-
modified PEI-PEG were larger compared to PEI and PEI-PEG polyplexes. However with 
sizes smaller then 200 nm it has been proven that the prePEGylation strategy allows the 
formation of nanosized polyplexes also with PEI-PEG-DMMAn-Mel conjugate. The addition 
of PEG 5000 resulted in partial shielding of the polyplexes. It is assumed that PEG with a 
higher MW (e.g. 20000)  is necessary for complete shielding of surface charge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: DNA binding of conjugates measured by ethidium bromide exclusion assay. Complexes 
were formed in the presence of EtBr in HBG and inhibition of EtBr/DNA fluorescence was monitored. 
The data points represent the average of two measurements. 
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Table 2: Particle size and zeta-potential of PEI-conjugate polyplexes. pDNA complexes were 
prepared in HBG at a N/P ratio of 6. pDNA concentration during polyplex mixing was 20 µg/ml. 
Polyplexes were allowed to stand for 20 – 30 minutes before measurement.   
 
After biophysical characterization, the influence of PEGylation and peptide-modification on 
levels of gene transfer efficiency in vitro was examined. Reporter gene expression (luciferase 
activity) and cellular toxicity were evaluated in two different tumor cell lines (Neuro2A, HUH7) 
after the application of different polyplex preparations (Fig. 20). For transfection experiments, 
all polyplexes were generated at a N/P ratio of 6. Polyplexes were generated in HBG at a 
pDNA concentration of 20 µg/ml during polyplex formation and the formulations (each 
containing 200 ng pCMVLuc DNA) were applied to the 10000 cells in medium containing 
10% FBS. After 3 h of incubation at 37 °C, transfection medium was replaced by fresh 
medium. 24 hours after initial transfection cells were assayed for luciferase expression. 
PEI showed similar transfection profiles in both cell lines. PEGylation had a 
disastrous effect: PEI lost its gene transfer activity. But after attachment of endosomolytic 
peptides to PEI-PEG gene transfer activity could be restored. PEI-PEG-DMMAn-Mel and 
PEI-PEG-INF showed a slightly decreased gene transfer activity on HUH7 cells in 
comparison to the results obtained on Neuro2A cells. Attachment of the non-endosomolytic 
peptide Succ-Mel (lytic activity of melittin irreversibly masked by stable modification of 
melittin’s primary amines with succinic anhydride) did not enhance gene transfer activity of 
PEI-PEG.   
 
 
 
 
 
 
 
 
Size 
[nm] 
Zeta-potential 
[mV] 
PEI  80 +/- 11 27 +/- 1 
PEI-PEG 90 +/- 13 11 +/- 4 
PEI-PEG-Mel 110 +/- 14 16 +/- 4 
PEI-PEG-DMMAn-Mel 184 +/- 21 15 +/- 1 
PEI-PEG-INF 188 +/- 12 14 +/- 3 
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Fig. 20: Transfection efficiencies of PEI-PEG-conjugate polyplexes on Neuro2A- and HUH7-
cells. Polyplex formulations with branched PEI 25 kDa, PEG 5000 and peptides were compared. 
Complexes were prepared in HBG at a DNA concentration of 20 µg/ml, N/P 6. 200 ng pCMVLuc DNA 
were applied per 10000 cells.  
 
In order to evaluate toxic effects of the different polyplex formulations, metabolic activity of 
treated cells was measured by MTT assay 24 h after initial transfection. The assay was 
performed in parallel to transfection experiments. Overall cell viability was not affected to a 
large scale. The polyplex formulation which induced the highest toxicity (PEI-PEG-Mel) 
reduced cell viability only to as low as 70% of untreated control cells (Fig.  21). This indicated 
that differences in transfection efficiency of polyplexes were not attributed to varying toxic 
effects of the formulations. 
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Fig. 21: Metabolic activity of Neuro2A cells after transfection with indicated polyplex 
formulations. Polyplexes with branched PEI 25 kDa, PEG 5000 and peptides were prepared in HBG  
at a DNA concentration of 20 µg/ml, N/P 6. Metabolic activity of untreated control cells was set to 
100%.  
 
3.2.2.2 PLL-PEG-conjugates 
Binding strength of the PLL-conjugates to pDNA was compared via EtBr exclusion assay. 
The effects of PEGylation and peptide-modification on the pDNA-binding ability were 
negligible. In general at a PLL epsilon-amino nitrogen to pDNA phosphate ratio (N/P) of 1.5 
complete pDNA-binding was observed (Fig. 22) 
 
 
 
 
 
 
 
 
Fig. 22: DNA binding of conjugates measured by ethidium bromide exclusion assay. Complexes 
were formed in the presence of EtBr in HBG and inhibition of EtBr/DNA fluorescence was monitored. 
The data points represent the average of two measurements 
 
Particle sizes were in the range of 80 to 200 nm with PLL-PEG-DMMAn forming the largest 
complexes. As observed with PEI-PEG-conjugates, the zeta-potential measurements confirm 
that application of PEG 5000 only leads to partial shielding of polyplexes (Table 3). 
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Table 3: Particle size and zeta-potential of PLL-conjugate polyplexes. Polyplexes were generated 
at N/P 2 in HBG. pDNA-concentration during polyplex mixing was 20 µg/ml. Polyplexes were allowed 
to stand for 20 – 30 minutes before measurement.  
 
Analogous to transfection experiments with PEI-PEG-peptide-conjugates, the transfection 
efficiencies of PLL-PEG-conjugate-polyplexes on Neuro2A cells were examined. As 
expected, PLL and PLL-PEG were not able to enhance reporter gene expression (Fig. 23). 
While attachment of endosomolytic peptides (DMMAn-Mel, Mel, INF) to PEI-PEG enhanced 
gene transfer activity in all cases, only PLL-PEG-polyplexes containing DMMAn-Mel 
mediated gene transfer activity. Transfection efficiency of PLL-PEG-DMMAn-Mel polyplexes 
at N/P ratios of 2 and 3 were remarkably high (over 1000-fold higher efficiency than e.g. PLL-
PEG-Mel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Transfection efficiencies of PLL-PEG-polyplex formulations on Neuro2a cells. Polyplex 
formulations with branched PLL 32000, PEG 5000 and peptides were compared. Complexes were 
prepared in HBG at a DNA concentration of 20 µg/ml, N/P ratios of 1 to 3. 200 ng pCMVLuc DNA was 
applied per 10000 cells.  
 
Metabolic activity of transfected cells was overall above 80% with the conclusion that 
differences in toxicity were not responsible for the great difference in gene transfer activity 
(Fig. 24). 
Polyplexes (N/P 2) Size [nm] Zeta-potential [mV] 
PLL 83 +/- 2 34 +/- 2 
 
PLL-PEG 87 +/- 14 
 
22 +/- 4 
 
PLL-PEG-Mel 111 +/- 12 
 
17 +/- 1 
 
PLL-PEG-DMMAn-Mel 203 +/- 15 
 
14 +/- 1 
 
PLL-PEG-INF 100 +/- 14 
 
15 +/- 3 
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Fig. 24: Metabolic activity of Neuro2A cells after transfection with indicated polyplex 
formulations. Polyplexes with PLL 32000, PEG 5000 and peptides were prepared in HBG at a DNA 
concentration of 20 µg/ml, N/P ratio 1 to 3. Metabolic activity of untreated control cells was set to 
100%.   
 
Particle size is known to influence in vitro gene transfer activity [138]. Thus additional size 
measurements were carried out after incubation of polyplexes in serum containing medium. 
These experiments were performed to clarify if polyplexes aggregate in cell culture medium 
after adding the polyplex solution at begin of transfection (Table 4).  
 Size [nm] 
Polyplexes (N/P 2) 0.1 hour 3 hours incubation in cell 
culture medium 
PLL 76 179 
PLL-PEG 91 187 
PLL-PEG-Mel 105 105 
PLL-PEG-DMMAn-Mel 190 178 
PLL-PEG-INF 135 109 
 
Table 4: Sizes of indicated PLL polyplexes after incubation in serum containing DMEM cell 
culture medium. Sizes represent the average of two measurements.  
 
PLL- and PLL-PEG-polyplexes increased in size, while size of PLL-PEG-peptide polyplexes 
did not alter in a large extent. Based on these observations it is supposed that changes in 
size after incubation in cell culture medium-containing solution were not responsibly for the 
observed differences in transfection efficiency.  
  Results  51 
 
PLL-PEG
control cells
PLL
PLL-PEG-INF
PLL-PEG-Mel
PLL-PEG-DMMAn-Mel
To determine if varying internalization rates led to differences in gene transfer activity, flow 
cytometry internalization studies were performed (Fig. 25). Neuro2A cells were incubated for 
3 h with PLL-polyplexes at 37 °C. Polyplexes were generated in HBG at N/P ratio of 2. After 
incubation cell culture medium was removed and trypsin treatment of cells was performed to 
remove surface-associated (but not internalized) polyplexes.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25: Flow cytometry of Neuro2A cells incubated with PLL/DNA complexes. Neuro2A cells 
(80000 cells in 1 ml cell culture medium) were incubated with PLL / Cy5-labeled DNA complexes (N/P 
2.0 in HBG), containing 1.5 µg of DNA for 3 h at 37 °C. Following incubation, the medium was 
removed, cells were washed with ice-cold PBS, treated with trypsin/EDTA, resuspended in ice-cold 
PBS and after addition of propidium iodide flow cytometry analysis was performed.  
 
Comparing cells incubated with PLL, PLL-PEG and PLL-PEG-peptide polyplexes reveals the 
highest degree of internalization in case of PLL-PEG-peptide polyplexes (PLL-PEG-DMMAn-
Mel, PLL-PEG-INF and PLL-PEG-Mel). PLL-PEG polyplexes showed a reduced and PLL-
polyplexes the lowest degree of internalization. 
In summary, PLL-PEG-DMMAn-Mel polyplexes displayed high gene transfer efficiency. PLL-
PEG-DMMAn-Mel polyplexes were slightly larger in size, but neither polyplex aggregation in 
cell culture medium nor a better internalization of PLL-PEG-DMMAn-Mel explained the 
remarkable gene transfer activity in comparison to the other PLL-PEG formulations.  
 
3.2.3 siRNA-delivery 
RNA interference strategies using siRNA is one of the most important discoveries in biology 
in the past years. There is a great demand in delivery systems for this biological 
therapeutics. It has to be pointed out that successful pDNA formulations are not naturally 
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suitable for siRNA delivery. For example Mixson and coworkers demonstrated that a 
branched carrier consisting of lysine and histidine residues designed for pDNA could not 
mediate delivery of siRNA [44]. Experiments to determine the biological activity and 
biophysical properties were carried out to evaluate the siRNA delivery efficiency of the 
synthesized endosomolytic conjugates. Biological siRNA transfection data were generated in 
collaboration with Alexander Philipp, as part of his PhD thesis (in preparation) where details 
will be described. The most important biological data are also presented within the following 
sections, to provide a complete view on chemical and biological characteristics of the 
conjugates. 
3.2.3.1 PEI-PEG-conjugates 
siRNA delivery efficiency of the conjugates was examined using a Neuro2A-eGFPLuc- 
(mouse neuroblastoma stably expressing luciferase) and a HUH7-eGFPLuc-cell line (human 
hepatoma stably expressing luciferase). siRNA was complexed with PEI conjugates in HBG 
at a siRNA concentration of 20 µg/ml. The experiments were carried out with each polymer 
bound to siRNA at different w/w-ratios. 48 h after initial transfection of 5000 seeded cells, 
cells were lysed and assayed for luciferase expression. 
As shown in Fig. 26, PEI (with or without PEG) did not mediate siRNA knockdown at both 
tested siRNA doses (0.25 and 0.5 µg). But after modification with DMMAn-Mel and INF-
peptide siRNA delivery efficiency was greatly enhanced as demonstrated by luciferase gene 
knockdown (Fig. 26a). This effect was more pronounced on HUH7-eGFPLuc cells (Fig. 27). 
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Fig. 26: siRNA gene silencing efficiency on stably luciferase expressing Neuro2A-eGFPluc 
cells. PEI conjugates were complexed with 500 ng (a) or 250 ng (b) siRNA at different PEI to siRNA 
ratios (w/w). Gray bars indicate transfection with luciferase siRNA. White bars indicate transfection 
with complexes containing control siRNA. Reduced gene expression with control siRNA indicates 
unspecific knockdown / carrier toxicity. Data were generated by Alexander Philipp as part of his PhD 
thesis (in preparation). 
 
Attachment of Mel did not enhance siRNA delivery activity on Neuro2A-eGFPLuc cells; on 
HUH7-eGFPLuc cells a slight knockdown effect was observed. Additional a PEI-PEG-
conjugate with a peptide lacking lytic activity (Succ-Mel) was tested. The activity profile was 
comparable to ineffective PEI-PEG-Mel. No knockdown activity was observed on Neuro2A-
eGFPLuc cells, only a slight knockdown on HUH7-eGFPLuc cells. In parallel, complexes with 
a control siRNA sequence were applied (white bars): if luciferase expression decreases upon 
transfection with control siRNA, “knockdown” is mainly due to carrier toxicity and can hereby 
be distinguished from a real protein knockdown effect. 
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Fig. 27: siRNA gene silencing efficiency on stably luciferase expressing HUH7-eGFPluc cells. 
PEI conjugates were complexed with 500 ng (a) or 250 ng (b) siRNA at different PEI to siRNA ratios 
(w/w). Gray bars indicate transfection with luciferase siRNA. White bars indicate transfection with 
complexes containing control siRNA. Reduced gene expression with control siRNA indicates 
unspecific knockdown / carrier toxicity. Data were generated by Alexander Philipp as part of his PhD 
thesis (in preparation). 
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Interaction of PEI-conjugates with siRNA was proven by EtBr exclusion fluorescence assay 
(Fig. 28). 
 
 
 
 
 
 
 
 
Fig. 28: siRNA binding of PEI-conjugates measured by ethidium bromide exclusion assay. 
Complexes were formed in the presence of EtBr in HBG and inhibition of EtBr/siRNA fluorescence 
was monitored. The data points represent the average of two measurements. 
 
Particle size of PEI, PEI-PEG, PEI-PEG-Mel and PEI-PEG-DMMAn-Mel siRNA polyplexes 
was measured by fluorescence correlation spectroscopy (FCS). For FCS experiments Cy5 
labeled siRNA was utilized. FCS detects spontaneous intensity fluctuations resulting from 
fluorescently labeled molecules diffusing through a highly focused laser illuminated volume 
within the sample. The size of this volume is fixed by the confocal detection optics and the 
excitation profile of the focused laser beam and characterized by calibration measurements 
against a standard of a known diffusion constant. The raw signal, the time dependent 
fluorescence intensity fluctuations, is time-autocorrelated to obtain dynamic information on 
the fluorescently labeled molecules / polyplexes and to calculate the hydrodynamic radius. 
The obtained results are displayed in Table 5. 
siRNA polyplexes size [nm] 
PEI w/w 0.5 93 – 2800 (high polydispersity) 
PEI w/w 1 20 +/- 8 
PEI-PEG w/w 0.5  10 +/- 3 
PEI-PEG w/w 1 15 +/- 8 
PEI-PEG-Mel w/w 0.5  30 +/- 2 
PEI-PEG-Mel w/w 1 10 +/- 2 
PEI-PEG-DMMAn-Mel w/w 0.5  89 +/- 13 
PEI-PEG-DMMAn-Mel w/w 1 26 +/- 4 
Table 5: Size of siRNA polyplexes. For FCS measurements Cy5 labeled siRNA was used. 
Polyplexes were generated in HBG at indicated polycation to siRNA ratios (w/w) 
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In general polyplexes prepared at w/w ratio of 1/1 were smaller than polyplexes generated at 
w/w 0.5. PEI-PEG formed the smallest polyplexes (10 – 15 nm). Aggregation was observed 
in case of PEI polyplexes generated at w/w 0.5. DMMAn-Mel polyplexes were larger in size 
(26 – 98 nm) than polyplexes containing unmodified melittin (10 – 30 nm).   
3.2.3.2 PLL-PEG-conjugates 
As expected, neither PLL- nor PLL-PEG-polyplexes showed siRNA delivery activity on 
Neuro2A-eGFPLuc-cells (Fig. 29). In contrast to modification of PEI-PEG, attachment of INF-
peptide did not enhance siRNA activity of PLL-PEG. Once more linkage of DMMAn-Mel 
enabled gene silencing (over 80% reduction of luciferase expression compared to Neuro2A-
eGFPLuc-cells treated with control siRNA containing PLL-PEG-DMMAn-Mel polyplexes). 
Notably PLL-PEG displayed remarkable toxicity at increasing polycation to siRNA ratios (as 
indicated by decrease of luciferase expression after transfection with control siRNA 
containing formulations).     
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29: siRNA gene silencing efficiency on stably luciferase expressing Neuro2A-eGFPluc 
cells. PLL conjugates were complexed with 250 ng siRNA at different PLL to siRNA ratios (w/w). Gray 
bars indicate transfection with luciferase siRNA, white bars indicate transfection with complexes 
containing control siRNA. Reduced gene expression with control siRNA indicates unspecific 
knockdown / carrier toxicity. Data were generated by Alexander Philipp as part of his PhD thesis (in 
preparation). 
 
The binding strength of conjugates to siRNA was assayed by EtBr-exclusion-assay (Fig. 25). 
Modification with peptides demanded a greater amount of polycation to completely bind the 
nucleic acid. At w/w 0.5 (corresponds approximately N/P 0.8) PLL-PEG-DMMAn-Mel showed 
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no nucleic acid binding which correlated with its non-existing delivery efficiency at this w/w-
ratio. 
 
 
 
 
 
 
 
 
Fig. 30: siRNA binding of PEI-conjugates measured by ethidium bromide exclusion assay. 
Complexes were formed in the presence of EtBr in HBG and inhibition of EtBr/DNA fluorescence was 
monitored. Each data point represents the average of two measurements. 
 
 
siRNA polyplexes size [nm] 
PLL w/w 1 29 +/- 11 
PLL w/w 2 18 +/- 9 
PLL-PEG w/w 1  8 +/- 1 
PLL-PEG w/w 2 7 +/- 1 
PLL-PEG-Mel w/w 1  8 – 430 (high polydispersity) 
PLL-PEG-Mel w/w 2 12 +/- 2 
PLL-PEG-DMMAn-Mel w/w 1  6 – 794 (high polydispersity) 
PLL-PEG-DMMAn-Mel w/w 2 40 +/- 26 
Table 6: Size of siRNA polyplexes. For FCS measurements Cy5 labeled siRNA was used. 
Polyplexes were generated in HBG at indicated polycation to siRNA ratios. FCS measurements were 
performed in cooperation with Claudia Schmidt, research group Prof. J. Rädler, Physics, LMU. 
 
Particle size of PLL, PLL-PEG, PLL-PEG-Mel and PLL-PEG-DMMAn-Mel siRNA polyplexes 
was measured by FCS (Table 6). Consistent with the results obtained with PEI-conjugates, 
polyplexes prepared at the lower w/w-ratio were larger in size. Again PEGylated formulations 
without peptide formed the smallest complexes (8 nm). Formulations containing the lytic 
peptides were larger.  
Combined PEGylation and DMMAn-Mel-modification of PEI and PLL enabled siRNA 
delivery. Hence the most promising conjugates (PEI-PEG-DMMAn-Mel and PLL-PEG-
DMMAn-Mel) were compared side-by-side in transfection experiments on Neuro2A-eGFPLuc 
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cells (Fig. 31). PLL-PEG-DMMAn-Mel showed the best gene knockdown activity (up to 90% 
gene silencing compared to untreated control cells). Treatment with PEI-PEG-DMMAn-Mel 
siRNA polyplexes led to 70% protein knockdown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31: siRNA gene silencing efficiency of PLL- and PEI-based conjugates. PLL- (a) PEI-based 
(b) conjugates on stably luciferase expressing Neuro2A-eGFPluc cells complexed with 500ng siRNA 
at different polycation to siRNA ratios (w/w). Gray bars indicate transfection with luciferase siRNA, 
white bars indicate transfection with complexes containing control siRNA. Reduced gene expression 
with control siRNA indicates unspecific knockdown / carrier toxicity. Data were generated by 
Alexander Philipp as part of his PhD thesis (in preparation). 
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Influence on metabolic activity was also assayed after transfection (Fig. 32). Treatment with 
PLL-PEG polyplexes at a high polycation to siRNA ratio resulted in a distinct reduction of 
metabolic activity, while cell viability of cells was not reduced after transfection with other 
tested formulations.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32: Metabolic activity of Neuro2A-eGFPLuc cells 48 hours after initial siRNA transfection 
with indicated polyplexes. Metabolic activity of untreated control cells was set to 100%. Data were 
generated by Alexander Philipp as part of his PhD thesis (in preparation). 
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3.3 Conjugate containing covalently attached siRNA for improved 
delivery 
3.3.1 Design and synthesis of the programmed siRNA carrier  
Non-viral nucleic acid vectors are commonly generated by the complexation of negatively 
charged nucleic acids with cationic polymers or cationic lipids. Thus electrostatic interactions 
hold the polyplex together. However - especially in vivo - the polyplex is faced with 
polyanions, e.g. negatively charged plasma proteins like soluble glycosaminoglycans or 
heparan sulfates of the extracellular matrix. Interaction of polyplexes with this polyanions can 
lead to vector unpackaging before the nucleic acid carrier reaches the target cell [52]. To 
ensure extracellular stability a siRNA delivery system containing covalently attached siRNA 
was synthesized. As linkage a bioreversible disulfide bond was chosen. After reaching the 
cytosol the intracellular reductive environment could break the bond and thus enable release 
of the siRNA. The siRNA was linked to PLL-PEG-DMMAn-Mel, which in the previous in vitro 
experiments turned out to be the most promising siRNA carrier. A schematic structure is 
shown in Scheme 3.  
 
 
 
 
 
 
 
 
 
Scheme 3: Schematic structure of PLL-PEG-DMMAn-Mel-siRNA 
Synthesis of PLL-PEG-DMMAn-Mel-siRNA was carried out similarly to the PLL-PEG-
DMMAn-Mel synthesis. In brief, thiol-modified luciferase siRNA (sense strand modified at the 
5’ end) was mixed with PLL-PEG-PDP. After reaction of thiol-siRNA with PDP-linkers, 
DMMAn-Mel was added to the mixture. To avoid aggregation of siRNA and DMMAn-Mel with 
PLL-PEG-PDP during synthesis, a high salt concentration (1.5 M NaCl) was applied. As 
previously mentioned PEG (MW 5000) could not be separated from branched PEI (25 kDa) 
by SEC. Because it was questionable if unbound siRNA (MW 13400) could be separated 
from the conjugate by size exclusion chromagraphy, a mock synthesis without covalent 
linkage was carried out. Unmodified siRNA was mixed with PLL-PEG-PDP and DMMAn-Mel. 
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After coupling of DMMAn-Mel the mixture containing PLL-PEG-DMMAn-Mel-PDP, free 
siRNA, DMMAn-Mel and low molecular weight impurities was loaded onto a Superdex 75 
column. Fig. 33 and 34 clearly show that separation of the mixture was possible. 
 
 
 
 
 
 
 
 
 
 
Fig. 33: Chromatogram of the PLL-PEG-DMMAn-Mel and siRNA-mixture. The mixture containing 
the siRNA-conjugate was loaded onto a Superdex 75 HR 10/30 column. The conjugate was eluted 
with 1M NaCl, 20mM Hepes, pH 8.2; flow rate: 0.5 ml/min. x-axis: elution volume; y-axis: absorption 
(dotted line: absorption at 260 nm. Solid line: absorption at 280nm). Peak 1: product conjugate; peak 
2: unbound siRNA (see Fig. 34)  
 
 
 
 
 
 
 
 
 
 
 
 
As expected mixing of siRNA and PLL-PEG-DMMAn led to complex formation (Fig. 34, lane 
2). However electrostatic interactions could be eliminated by heparin (Fig. 34, lane 3). Free 
siRNA was only present in peak 2 (Fig. 34, lanes 6 and 7) and hence could be separated 
from the PLL-PEG-DMMAn-Mel conjugate by SEC.  
After establishing the reaction and purification protocol, synthesis was conducted 
analogously with the thiol-modified siRNA. First thiol-modified GL3 luc siRNA was mixed with 
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Fig. 34: Agarose gel electrophoresis of peaks 1 and 
2 from Fig. 33. 1: 0.5 µg siRNA; 2: PLL-PEG-DMMAn-
Mel siRNA polyplex (w/w 2); 3: like 2 plus heparin; 4: 
Peak 1; 5: Peak 1 plus heparin; 6: peak 2; 7: peak 2 
plus heparin   
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PLL-PEG-PDP. After 1 h released pyridine-2-thione was measured at 343 nm to determine 
the degree of modification with siRNA (approximately 1.5 siRNA / 1 PLL). Subsequently 
DMMAn-Mel was coupled to the remaining PDP-groups and the siRNA-conjugate was 
loaded onto a Superdex 75 size exclusion column for purification. Fig. 35 shows the 
chromatogram of the SEC purification. 
 
 
 
 
 
 
 
 
 
 
Fig. 35: Chromatogram of the PLL-PEG-DMMAn-Mel-siRNA purification. The mixture containing 
the siRNA-conjugate was loaded onto a Superdex 75 HR 10/30 column. The conjugate was eluted 
with 1M NaCl, 20mM Hepes, pH 8.2; flow rate: 0.5 ml/min. x-axis: elution volume; y-axis: absorption 
(dotted line: absorption at 260 nm. Solid line: absorption at 280nm). Peak 1: product conjugate; peak 
2: unbound siRNA  
 
In comparison with the chromatogram obtained after synthesis with unmodified siRNA (Fig. 
33) a significant smaller amount of free siRNA (peak 2) was found, which is due to 
conjugation of a large part of thiol-modified siRNA to PLL-PEG-PDP. The fractions containing 
the conjugate were pooled and snap-frozen in liquid nitrogen. The purified PLL-PEG-
DMMAn-Mel-siRNA conjugate had a molar ratio of approximately 1 / 1 / 7,5 / 1,5 (PLL / PEG 
/ DMMAn-Mel / siRNA). This batch was used for the transfection experiments. A second 
batch was synthesized analogously, however after SEC-purification the conjugate was frist 
desalted by dialysis against HBG (pH 8.2). Not before desalting, this conjugate was snap-
frozen in liquid nitrogen. 
Additional, a conjugate containing Dharmacon’s non-targeting control#3 siRNA was 
synthesized for transfection experiments. This control-conjugate was purified and handled 
like the first batch. Briefly, after SEC-purification it was snap-frozen in liquid nitrogen without 
further desalting. The composition was comparable to the GL3 luc conjugate: 1 / 1 / 6 / 1.3 
(molar ratio of PLL / PEG / DMMAn-Mel / siRNA).    
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Covalent attachment of siRNA or rather absence of free siRNA in the conjugate were 
checked by agarose gel electrophoresis (Fig. 36).  
 
 
 
 
 
 
 
 
 
 
Fig. 36: Agarose gel electrophoresis of purified PLL-PEG-DMMAn-Mel-siRNA conjugate. 1: 0.25 
µg siRNA; 2: 0.5 µg siRNA; 0.5 µg siRNA + heparin + TCEP; 4: free lane; 5: PLL-conjugate (2.4 µl of 
peak 1, Fig. 35) 6: peak 1 plus TCEP; 7: peak 1 plus heparin; 8: peak 1 plus heparin and TCEP; 9: 
free lane; 10: PLL/siRNA-polyplex (w/w 2); 11: PLL/siRNA-polyplex plus TCEP; 12: PLL/siRNA-
polyplex plus heparin; 13: PLL/siRNA-polyplex plus heparin and TCEP; 14: free lane; 15: 20µl of peak 
2, Fig. 35  
 
From untreated conjugate (Fig. 36, lane 5) no siRNA is released during agarose gel 
electrophoresis. Neither TCEP nor heparin pretreatment alone could induce a release of 
siRNA (Fig. 36, lane 6 and 7, respectively). Only if reducing conditions and heparin treatment 
are combined siRNA is released from the PLL-PEG-DMMAn-Mel-siRNA conjugate (Fig. 36, 
lane 8). In contrast, heparin treatment alone could already unpackage a conventional 
electrostatic complexed PLL/siRNA polyplex (Fig, 36, lane 12).         
3.3.2 siRNA delivery efficiency and cytotoxicity 
siRNA delivery effficiency of the conjugate was evaluated on Neuro2A-eGFPLuc-cells and  
compared with an equal formulation apart from the fact that luciferase and control siRNA 
were electrostatically complexed (Fig. 37). In parallel cell viability of cells was assayed using 
a MTT assay (Fig. 38). 
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Fig. 37: siRNA gene silencing efficiency of PLL-PEG-DMMAn-Mel-siRNA. Protein knockdown of 
the conjugate was compared with knockdown activity of PLL-PEG-DMMAn-Mel electrostatically 
complexed at w/w ratio of 2 with indicated amounts of siRNA. Grey bars indicate transfection with 
luciferase siRNA, white bars indicate transfection with control siRNA. Data were generated by 
Alexander Philipp as part of his PhD thesis in preparation. 
 
With the PLL-PEG-DMMAn-Mel / luc siRNA-polyplex (complexed at w/w ratio 2) a 90% 
reduction of luciferase expression could be observed. The conjugate containing covalently 
linked GL3 luc siRNA enabled 80% luciferase knockdown at lower siRNA doses (0.125 and 
0.25 µg) and a 90% knockdown at higher siRNA amounts (0.5 – 1 µg). At the highest siRNA 
dose (1 µg) the luciferase knockdown effect is not only based on RNAi: also with control 
siRNA the luciferase expression is reduced, indicating unspecific protein knockdown caused 
e.g. by carrier toxicity. 
Most recently, the covalent conjugate of non-targeting control#3 siRNA was also tested in the 
luciferase cell assay. Consistent with the concept of specific siRNA knock down, no reduction 
of luciferase activity was observed, unless the high 1 µg dose was applied (Alexander 
Philipp, unpublished results).  
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Fig. 38: Cell viabiliy after transfection with PLL-PEG-DMMAn-Mel-siRNA and the corresponding 
formulation containing electrostatically complexed siRNA. 5000 seeded Neuro2A-eGFPLuc-cells 
were treated with formulations containing indicated amounts of siRNA. 48 hours after initial 
transfection metabolic activity of cells was evaluated by a MTT assay. Data were generated by 
Alexander Philipp as part of his PhD thesis in preparation. 
 
This observation was also reflected in the MTT assay. While cells maintened a high 
metabolic activity at siRNA doses from 0.125 µg to 0.75 µg, the metabolic activity was 
reduced significantly at the highest applied siRNA dose. In direct comparison, the PLL-
siRNA-conjugate showed a reduced cytotoxicity (over 70% metabolic activity after treatment 
with 1 µg siRNA in contrast to 50% metabolic activity in case of the polyplex formulation).  
3.3.3 Glutathione induced release of siRNA  
In the above described agarose gel electrophoresis study (Fig. 36) TCEP was used as 
reducing agent. Compared to DTT, TCEP is more stable, more effective, and able to reduce 
disulfide bonds at lower pH. However it presents artificial, unnatural conditions. The less 
effective glutathione (GSH) is nature’s reducing agent which is found in millimolar 
concentrations in the cytosol (1 – 10 mM) [139]. In the extracellular environment only 
micromolar concentrations are present. To clarify if release of siRNA is possible in cells, the 
conjugate was incubated at 37 °C with physiological glutathione concentrations and release 
of siRNA was monitored by agarose gel electrophoresis (Fig. 39).  
In a side by side comparison of GSH-incubated and untreated siRNA it was found out that 
incubation with GSH weakened the EtBr-siRNA-fluorescence (data not shown). This can also 
be seen at lanes 1 (GSH-incubation of 0.5µg siRNA) and 4 (TCEP-incubation of conjugate 
PLL-PEG-DMMAn-Mel 
polyplex 
PLL-PEG-DMMAn-Mel-siRNA 
conjugate 
siRNA 
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containing ~ 0.5 µg siRNA). Interestingly incubation with both TCEP and GSH did not 
weaken the fluorescence (lane 5). At GSH-concentrations of 1.25 to 5 mM released siRNA 
could be detected. At higher GSH – concentrations no released siRNA could be detected, 
remarkably after incubation of the conjugate at 200 mM GSH no fluorescence could be 
observed at all (lane 13). Detection of siRNA was not possible under the influence of high 
GSH concentrations. 
 
 
 
 
 
 
 
 
 
Fig. 39: Agarose gel electrophoresis of PLL-PEG-DMMAn-Mel-siRNA conjugate after 
glutathione treatment. The conjugate was preincubated for 75 minutes at 37 °C with different 
glutathione amounts (cytosolic glutathione concentration: 1 to 10 mM). 1: 0.5µg siRNA + heparin + 
GSH (20 mM); 2: free lane; 3: 2.4 µl conjugate; 4: 2.4µl conjugate + heparin + TCEP; 5: 2.4µl 
conjugate + heparin + TCEP + GSH (20 mM); 6: free lane; 7: 2.4µl conjugate + heparin + GSH (1.25 
mM); 8: 2.4µl conjugate + heparin + GSH (2.5 mM); 9: 2.4µl conjugate + heparin + GSH (5 mM); 10: 
2.4µl conjugate + heparin + GSH (10 mM); 11: 2.4µl conjugate + heparin + GSH (20 mM); 12: free 
lane; 13: 2.4µl conjugate + heparin + GSH (200 mM) 
 
To prove the fluorescence eliminating effect, GSH was added stepwise to a fluorescent EtBr-
siRNA-solution (Fig. 40). At GSH-concentrations above 12 mM fluorescence dropped 
abruptly. In a control experiment water in corresponding volume was added (data not 
shown). 
 
 
 
 
 
 
   
 
 
21 bp  
(siRNA) 
Fig. 40: Influence of GSH-concentration on EtBr-
siRNA fluorescence. To 20 µg of siRNA in 2 ml 
EtBr-solution (0.4 µg/ml EtBr in HBG) GSH was 
added stepwise at RT. 30 seconds after each 
addition fluorescence was measured.  
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The same assay was performed with GelRed, a more conventient environmentally safe EtBr 
alternative. But GSH-addition also led to a constant decrease in fluorescence (data not 
shown). 
In summary, glutathione treatment at 37 °C could induce release of siRNA from the PLL-
PEG-DMMAn-Mel-siRNA-conjugate, however exact quantification was hardly possible due to 
the observed GSH-induced fluorescence variation. 
3.3.4 Particle size 
With respect to in vivo toxicity and passive targeting, size of the conjugate / particle is of 
considerable interest. Because size of the formulation can depend on parameters like salt-
concentration and / or freeze-thaw-processes, size was determined by DLS at different 
formulation steps. Directly after SEC before freezing the conjugate formed  80 nm particles in 
1M NaCl. After snap-freezing and thawing, size increased to 150 nm. When the unfrozen 
sample was diluted to 0.5 M NaCl and 0.15 M NaCl sizes grew to 300 nm and 250 nm, 
respectively. When 5% glucose was added to the 1 M NaCl-solution directly after SEC before 
freezing, the size of the main fraction did not change (80 nm), but some larger particles of 
different sizes were found (e.g. 600 nm). During the dialysis process against HBG pH 8.2, 
the conjugate is faced with salt concentrations which favor aggregation (0.15 – 0.5 M NaCl). 
Dialysis at 4 °C for 4 hours immediately after SEC before freezing resulted in 150 nm 
particles. Freezing and thawing of the conjugate in HBG did not change particle size. In 
summary, the PLL-PEG-DMMAn-Mel-siRNA conjugate formed particles in the range of 80 – 
300 nm, monomolecular structures could not be detected in DLS experiments.  This 
important formulation subject is currently being evaluated by the succeeding PhD thesis 
(Christian Dohmen, work in progress). 
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4 Discussion  
4.1.1 DMMAn-Mel-modification enhances pDNA transfer efficiency and 
reduces cytotoxicity of PLL   
The development of dynamic formulations (‘artificial viruses’) is a key issue in the field of 
nucleic acid delivery [112;140;141]. The intracellular dynamic behaviour of viruses, which 
have naturally evolved for delivery of their nucleic acid payload and their replication, can 
serve as inspiring example for the design of gene carriers. 
Poor endosomal release and toxicity of the carrier limit the application of non-viral gene 
transfer systems. A variety of endosomolytic peptides have been evaluated for the 
enhancement of nucleic acid delivery. Among those for example the acidic peptide GALA 
[105] possesses a most favorable pH-specific lytic activity. The acidic influenza derived 
peptide INF7 shows pH-specific high activity also on natural erythrocyte membranes and 
strongly enhances polylysine-mediated gene transfer [97]. The acidic, anionic nature of INF7 
however also causes problems for formulation with DNA: PLL-INF7 conjugates similar to 
those described previously [99] formed DNA complexes which were unstable and resulted in 
strong particle aggregation (data not shown). The cationic membrane-active peptide melittin 
does not display this problem; covalent melittin-polycation conjugates are well soluble and 
mediate strongly increased gene transfer activity [102;142]. 
Melittin displays similar highly efficient activity on biological membranes as INF7; however, it 
is not pH-specific. Lytic activity in the extracellular environment is unfavorable as it mediates 
toxic side effects [104]. To overcome this problem, Rozema et al. used an amine-reactive 
carboxylated dialkylmaleic anhydride derivative (2-propionic-3-methylmaleic anhydride, 
CDM) to mask the lytic activity of melittin at neutral pH which was restored after acidic 
cleavage of the protecting groups [129]. As described in 1967, maleic anhydrides reversibly 
react with the lysine residues and the N-terminal amino group of peptides and are removed 
again at slightly acidic, endosomal pH [143]. CDM represents a not commercially available 
dialkylmaleic anhydride derivative (Fig. 44). Rozema et al. state in their published work that 
only CDM, but not the commercially available inexpensive DMMAn is sufficient for masking 
the lytic activity of melittin.   
However the same group (Mirus Corporation) published the results of a hemolysis assay in 
US patent Nr. 6630351 where the presented data suggest that DMMAn is suitable for 
masking melittin’s lytic activity. No pDNA delivery studies were performed, and no covalent 
incorporation into cationic polymer carriers were tested. Aim of the current study was (i) to 
evaluate whether DMMAn-shielding of melittin is effective and pH-specific and (ii) to build on 
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the concept by now covalently linking a masked melittin peptide to a pDNA-binding 
polycation for polyplex formation. 
 
 
 
 
 
Fig. 44: Structures of CDM and DMMAn. DMMAn: dimethylmaleic anhydride; CDM: 2-propionic-3-
methylmaleic anhydride [129]  
 
Although the developed polymers in our group were more or less all OEI- or PEI-based, PLL 
was chosen as backbone polymer. In contrast to ethylenimine-containing polymers, PLL 
possesses no innate endosomal escape mechanism and as a consequence shows a very 
low gene transfer efficiency. In previous works melittin and analogs were linked to PEI 
[101;103;104]. On the one hand this is comprehensible because PEI for itself is highly 
effective in gene transfer and the most-frequently used polycation. But on the other hand if 
the influence of endosomolytic active agents wants to be analyzed, a combination with an 
endosomal escape inducing polymer might lead to synergistic effects and as a consequence 
complicate the evaluation. Thus, to “isolate” the endosomolytic effect, DMMAn-masked 
melittin was linked to PLL, yielding the conjugate PLL-DMMAn-Mel. For comparison 
unmodified melittin was also coupled to PLL; such a conjugate also has not been described 
previously.  
In a preliminary experiment melittin was modified with DMMAn end erytrocyte leakage 
activity was monitored. DMMAn-modification resulted in reduced lytic activity at neutral pH 
and a to unmodified melittin comparable lytic activity at pH 5. This demonstrates that DMMAn 
is an appropriate reagent for reversible masking of melittin’s lytic activity. In contrast to 
maleic and monomethylmaleic anhydrides, which produce an irreversible modification of 
sulfhydryl groups, dimethylmaleic anhydride does not cause a stable modification of thiol 
compounds. This behavior makes dimethylmaleic anhydride a specific reagent for the 
peptide amino groups [144]. Erythrocyte leakage assay (Fig. 9) demonstrated that also PLL-
DMMAn-Mel (in contrast to PLL-Mel) has a relatively low lytic activity at physiological pH over 
the whole tested concentration range. This is not self-evident because linkage of a polycation 
can change the endosomolytic properties [103]. The lytic activity could be restored almost to 
the level of PLL-Mel after preincubation at endosomal pH. These results prove that 
dimethylmaleic anhydride shielding can be used to generate bioresponsive conjugates with 
the desired lytic activity profile.  
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The lack of endosomolytic properties in case of PLL correlates with its low gene transfer 
activity. In contrast, both melittin conjugates greatly enhanced the gene transfer efficiency. A 
positive effect was also observed with a targeting ligand (transferrin) and a PEG shield within 
the polyplex formulation (Fig. 12). Such targeting and shielding domains have been found 
advantageous for in vivo gene delivery. While PEG shielding is very advantageous for 
polyplex stability, inhibition of undesired interactions or long systemic circulation after i.v. 
administration, it regrettably hampers intracellular trafficking and overall can reduce the 
transfection efficiency of the polyplex. To overcome this problem a pH-reversible PEG 
shielding can be applied. After reaching the acidic intracellular environment the PEG shield is 
removed. This strategy has been successfully applied for PEI polyplexes in vitro and in vivo, 
pH-reversible linkage improved gene transfer efficieny in comparison to stable shielded 
polyplexes [120]. In this work polyplexes containing both pH-dependent endosomolytic 
peptide and pH-reversible PEG shielding were also tested, however the usage of pH-
reversible in comparison with stable linked PEG did not further improve gene transfer. In 
consideration of the fact that stable PEG shielding did not decrease transfection efficiency of 
the tested polyplexes (Fig. 12) this finding is not surprising: pH-reversible PEGylation for 
itself cannot enhance luciferase gene expresssion, it just can avoid the negative effect of 
stable PEG shielding on gene transfer activity. Futhermore confocal laser scanning 
microscopy pictures of the targeted and PEGylated polyplexes containing labeled pDNA 
were acquired. After 3 and 24 hours polyplexes were found located in endosomal vesicles, 
but no spreaded fluorescence could be detected in the cytoplasm (data not shown). This 
indicates that endosomal escape is still a rare event even if gene transfer enhancing 
endosomolytic peptides are applied.    
To investigate the effect of endosomal acidification on the gene transfer activity, bafilomycin 
A1, an inhibitor of vacuolar ATPase endosome pumps, was included in transfection 
experiments. The efficiency of the gene carrier PEI relies on the “proton sponge” effect upon 
acidification of the endosomal compartment. Consistent with published literature [145] 
inhibition of acidification by bafilomycin A1 strongly reduced the gene transfer activity. 
Bafilomycin A1 did not alter gene transfer of PLL polyplexes which lack proton sponge 
activity. Interestingly, bafilomycin enhanced gene transfer activity of the PLL-Mel conjugate. 
This can be explained by the higher lytic activity of melittin at neutral pH than at acidic pH. 
Gene transfer by PLL-DMMAn-Mel was only slightly reduced by bafilomycin treatment. At 
first sight this incomplete inhibition seems to contradict the previous findings that 30 min 
incubation of erythrocytes with masked melittin does not result in lysis and that bafilomycin 
A1 can inhibit membrane lytic activity of masked melittin when incubated with cells for 10 min 
[129]. However, we observed an increase in erythrocyte lytic activity of DMMAn-Mel at 
neutral pH after a longer incubation period (2.5 h at 37 °C). Taken all together PLL-DMMAn-
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Mel data are consistent with a slow unmasking of melittin at neutral pH in the presence of 
bafilomycin inhibitor. The lack of fast acidic pH-triggered unmasking seems to counteract the 
enhancing effect of bafilomycin A1 as seen with non-masked PLL-Mel. A slow unmasking of 
melittin at neutral pH over a longer time period should be sufficient in terms of reduction of 
the acute toxicity, since polycationic gene carriers will be cleared from the blood circulation 
system and extracellular space within relatively short periods [146;147]. It also might ensure 
enhanced transfection efficiency upon intracellular trafficking of polyplexes into non-acidic 
intracellular vesicles.  
Apart from poor endosomal release also cytotoxicity of gene vectors is one of the limiting 
barriers to systemic non-viral nucleic acid delivery. High lytic activity of polymers before 
reaching their target enforces the problem. To address this issue relative metabolic activity of 
conjugate treated cells was determined via MTT assay (Fig 14). It has to be emphasized that 
the transfection experiments were performed at rather low polymer concentrations (2.4 µg/ml 
at N/P 2). Toxicity effects might be disguised at low concentrations, and higher polymer 
amounts might also be necessary for in vivo delivery. Hence toxicity was studied over a 
broad concentration range. Notably, PLL-DMMAn-Mel was much better tolerated by cells 
resulting in higher metabolic activity than PLL and PLL-Mel. To further evaluate the 
differences in toxicity we performed a LDH release assay (Fig 16). The result confirmed that 
PLL-DMMAn-Mel is the conjugate with the lowest acute toxicity. As expected, PLL-Mel 
mediated the highest LDH release. Remarkably, PLL-DMMAn-Mel released less LDH than 
the non-endosomolytic PLL. In accordance with the observed visible changes in cellular 
morphology PLL-Mel is the most toxic conjugate. It has to be mentioned that at higher 
polymer concentrations LDH release might also be enhanced because of cell necrosis and 
not only due to conjugate induced membrane interaction and pore formation. But also at low 
concentrations (0 to 5 µg/ml) where cells are viable according to the metabolic activity assay 
differences in LDH release are detectable. The observed results are in agreement with 
recent work on the interactions of polycations with lipid bilayers and cell membranes 
[148;149]. PLL can induce lipid bilayer nanoscale pore formation and thus enhances 
membrane permeability due to its regular positive charges. When the polycation is grafted 
with DMMAn-Mel, parts of the regular polycationic positive charges are masked and acute 
toxicity and membrane-disruptive interactions are decreased. In contrast, standard melittin 
which on its own can mediate cell membrane disruption (as measured by LDH release; Fig. 
17) upon conjugation adds lytic activity to the polymer. The data proves that DMMAn 
shielding of melittin not only avoids the undesired lytic activity in the extracellular 
environment, but also further reduces acute toxicity of the core polycation PLL which is 
advantageous particularly with regard to systemic in vivo delivery.  
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In summary, PLL-DMMAn-Mel represents a dynamic gene transfer system based on the 
polycation PLL with triggered endosomal lytic activity. Both melittin and DMMAn-Mel 
enhance gene transfer activity, but while melittin increases toxicity, DMMAn-Mel grafting 
even lowers the polycation cytotoxicity. In the following work, this promising strategy was 
also applied to other polymeric nucleic acid carriers. 
4.1.2 PEGylation and peptide modification of polycations: impact on 
pDNA and siRNA delivery  
PEI is one of the most frequently used polycations for non-viral gene delivery. PEI polymers 
can be synthesized with a branched or a linear structure and are available in a wide range of 
molecular weights. In this study branched PEI (25 kDa) was modified with DMMAn-Mel. 
However it was not possible to generate small nanosized nucleic acid polyplexes with PEI-
DMMAn-Mel. Modification of PEI with the negatively charged DMMAn-Mel peptide induced 
polymer collapse and polyplex aggregation (> 1µm, colloidal solution after SEC). DMMAn-
Mel has a net negative charge of -3 (unmodified melittin a net positive charge of +5). The 
negative charge favors interactions with the polycation. If peptides are grafted in a high 
density onto a polycation this can result in polymer aggregation. The same was observed 
when the negatively charged influenza peptide was grafted in high ratios on PLL (personal 
communication, E. Wagner); high ionic strength had to be applied during synthesis [99]. This 
handling difficulty was one of the reasons why Ogris et al. introduced the cationic peptide 
melittin, although it does not feature the desired pH-dependent lytic activity [101]. In general 
large particles are unfavored for intravenous administration. To overcome the aggregation 
problem, the PEI polymer was prePEGylated before peptides were attached. For polyplex 
shielding usually PEG with a high MW (e.g. 20 kDA) is used. The main intention of the 
PEGylation certainly was not shielding / reduction of surface-charge but rather solubility 
improvement and prevention of aggregation. For that reason PEI primarily was modified with 
PEG 5000. After this prePEGylation the SPDP linkers and subsequently DMMAn-Mel 
peptides were coupled. This strategy turned out to be successful, the PEI-PEG-DMMAn-Mel 
conjugate (molar ratio of PEI/PEG/DMMAn-Mel ~ 1/1.5/8) formed pDNA polyplexes in HBG 
with an adequate size (< 200 nm). Encouraged from this finding, the negatively charged INF 
peptide also was coupled successfully to PEI-PEG. The conjugates of the first series of 
synthesis were PEI-PEG, PEI-PEG-DMMAn-Mel, PEI-PEG-Mel and PEI-PEG-INF. With this 
conjugates different characteristic endosomolytic properties can be compared (e.g. pH-
dependent vs. static lytic activity).  
However conjugation of peptides not only changes the lytic activity of polymers, it also alters 
physicochemical properties like charge density or molecular weight of the conjugates which 
again can result in different polyplex characteristics. If worst comes to worse an improved in 
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vitro gene transfer efficiency of a polyplex containing an additional targeting peptide can be 
just the consequence of e.g. a different size of the polyplex and not of the introduced intrinsic 
targeting ability. In general this has to be kept in mind if transfection experiments are 
interpreted. To cope with this aspect, succinicanhydride modified melittin was linked to PEI-
PEG. Succinicanhydride reacts (like DMMAn) with the primary amines of melittin and 
eliminates the lytic activity of melittin, but in contrast to acid-sensitive DMMAn the 
modification is irreversible. As a result PEI-PEG-SuccMel should possess due to its melittin-
grafting similar properties like PEI-PEG-DMMAn-Mel, except for the fact that the protecting 
group is not cleavable. PEI-PEG-Succ-Mel was used as negative control in transfection 
experiments.   
With regard to cytotoxicity, DMMAn-Mel modification of PEI-PEG had similar effects 
comparable to DMMAn-Mel modification of PLL: After incubation of Neuro2a cells with 
conjugates, DMMAn-Mel modified PEI-PEG induced less LDH-release than PEI-PEG-Mel or 
PEI-PEG (Fig. 18). Modification with the negatively charged and at neutral pH unlytic 
influenza peptide also reduced LDH-release.  
pDNA transfection efficiency was evaluated on Neuro2A- and HUH7-cells. PEI polyplexes 
showed good transfection efficiency. PEGylation had a disastrous effect: PEI lost its gene 
transfer activity; PEI-PEG polyplexes only reached background levels of luciferase 
expression (Fig. 20). This phenomenon was investigated in detail by Mishra and coworkers. 
Both unmodified and PEGylated particles enter cells through the endocytic pathway and 
accumulate in a perinuclear region. The overall cellular uptake of polyplexes was similar, but 
when unPEGylated PEI polyplexes were applied, more PEI per endosome was found. In 
case of PEI-PEG polyplexes the amount of PEI per endosome was too low to mediate 
buffering and endosomal escape [91]. But after attachment of DMMAn-Mel, Mel and INF to 
PEI-PEG gene transfer activity was restored. Conjugation of Succ-Mel did not improve gene 
transfer activity. This indicates that the added endosomolytic properties are responsible for 
the gene transfer enhancement; adding a similar structured peptide without lytic activity 
(Succ-Mel), which might influence the biophysical properties of the polyplex, is not sufficient.   
Size of the polyplexes ranged from 80 nm to 190 nm. Polyplexes containing negatively 
charged peptides formed the largest polyplexes (190 nm). The polyplexes were generated at 
N/P 6 in HBG at a pDNA-concentration of 20 µg/ml during complex formation. For 
transfection experiments the polyplexes were prepared under the same conditions. This is an 
important issue, because the conditions during complex formation can have an influence on 
the size of the nucleic acid formulation. PEGylation reduced the zeta-potential in comparison 
to PEI-polyplexes. However all PEGylated polyplexes were only partially shielded. It is known 
that PEGylation can almost neutralize the surface charge of polyplexes [121], but for this 
purpose PEG with a higher MW has to be applied (e.g. PEG 20000). The remaining positive 
  Discussion  74 
 
surface charge contributes to the polyplex-cell-interaction, which is important in terms of 
association and internalization because no additional targeting ligand is incorporated into the 
formulation. 
Endosomal escape is not only required for pDNA delivery, also siRNA polyplexes are 
endocytosed and release of the endocytosed material into the cytoplasm is mandatory. For 
that reason, siRNA delivery efficiency of the synthesized endosomolytic conjugates was 
investigated. While PEI is effective in pDNA delivery, no siRNA delivery activity was 
observed on Neuro2A-eGFPLuc- and HUH7-eGFPLuc cells (Fig. 26 and 27). PEGylation 
alone did not improve siRNA delivery activity. But after modification of PEI-PEG with 
DMMAn-Mel and INF-peptide siRNA delivery efficiency was greatly enhanced as 
demonstrated by luciferase knockdown (~ 70% protein knockdown). As expected, 
modification with Succ-Mel did not improve gene silencing. Interestingly, PEI-PEG-Mel was 
not effective (despite the fact that pDNA-transfer efficiency was enhanced with melittin). 
Beside endosomal escape, polymer-siRNA complex dissociation was discussed as barrier in 
siRNA delivery  [150;151]. A positively charged peptide (like Mel) could lead to a too strong 
siRNA association, while negatively charged DMMAn-Mel and INF reduce the binding strength of 
PEI so that dissocation in the cytoplasm can take part. However recently published results 
suggest that the opposite – a too low stability of the siRNA polyplex – is a major drawback [52-
54]. Hence the reason for the found difference in pDNA- and siRNA-delivery activity of PEI-
PEG-Mel stays unclear. In general the gene silencing effect was more pronounced in HUH7-
eGFPLuc cells. 80 % protein knockdown was achieved with PEI-PEG-DMMAn-Mel and PEI-
PEG-INF polyplexes. Even with PEI-PEG-Mel and -Succ-Mel a slight protein knockdown 
could be observed with this cell line. In both cell lines luciferase expression was not reduced 
when experiments were performed with non-targeting control siRNA, which demonstrates 
that protein knockdown of PEI-PEG-DMMAn-Mel and PEI-PEG-INF is not due to carrier 
toxicity. This was confirmed by a MTT assay at the end of transfection which proved that 
metabolic activity of Neuro2A-eGFPLuc cells was not affected in a large extent (Fig. 31).   
Differences in polyplex size can explain differences in delivery activity. Size of selected 
siRNA-polyplexes was measured by fluorescence correlation spectroscopy (FCS). Usually 
dynamic light scattering (DLS) was used for determining the hydrodynamic radius of the 
polyplexes. However only poor data quality could be obtained with DLS, the results were not 
reliable. If the the particles are small (e.g. 10 nm) and the concentration is too low, only a low 
intensity / poor data quality can be obtained with DLS. Fig. 45 shows exemplarily the DLS 
results of two different formulations. Panels of (a) display the raw correlation and size 
distribution data of an evaluable measurement, (b) shows inappropriate results obtained with 
small siRNA polyplexes. One feasible solution would be to use more siRNA / a higher 
polyplex concentration for the size measurements (in general the Zetasizer Nano ZS is 
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capable to measure sizes in the area of 5 nm, as demonstrated by measurement of a 
concentrated albumin solution), but the (low) concentration during polyplex formation limits 
the concentration during measurement (additional the available siRNA and conjugate 
amounts are limited). 
45 a ) 
 
 
 
 
 
 
 
45 b ) 
 
 
 
 
 
 
 
Fig. 45: Exemplary dynamic light scattering results of nucleic acid formulations. Panels of (a) 
display the raw correlation and size distribution data of a valid measurement, (b) shows inappropriate 
results obtained with small siRNA polyplexes. 
 
Therefore fluorescence correlation spectroscopy (FCS) was chosen as method to evaluate 
the size of this siRNA polyplexes. FCS detects spontaneous intensity fluctuations resulting 
from fluorescently labeled molecules diffusing through a highly focused laser illuminated 
volume within the sample. Measured diffusion times (of Cy5-labeled polyplexes)
 
were used to 
calculate the hydrodynamic radius. As displayed in Table 5, PEI-PEG formed polyplexes with 
10 and 15 nm (at w/w ratios of 0.5 and 1). PEI-PEG-DMMAn-Mel polyplexes were larger. At 
w/w-ratio of 0.5 polyplexes had a size of 89 nm, at w/w 1 a size of 26 nm. This size 
difference might explain why PEI-PEG-DMMAn-Mel mediates siRNA delivery; however non-
transfecting PEI polyplexes prepared at w/w 0.5 were also large in size and highly 
polydispers (93 – 2800 nm). Additional PEI-PEG-Mel forms particles at w/w 0.5 with a similar 
size like PEI-PEG-DMMAn-Mel generated at w/w 1, but PEI-PEG-Mel polyplexes did not 
work for siRNA delivery.  
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Altogether, the results suggest that differences in siRNA delivery activity are not mainly 
based on size differences of polyplexes.  
PEI’s are among the most efficient non-viral gene vectors that have been developed for in 
vitro and in vivo delivery because they reconcile several attributes which are necessary for 
efficient gene transfer, namely nucleic acid complexation, protection from nucleases, cell 
internalization, endosomal buffering / escape and release of pDNA. Accordingly people 
hazard the consequences of using a non-biodegradable polymer like PEI because the 
polymers show good transfection efficiencies even without extensive modification. But as 
demonstrated, branched PEI on its own was not effective in siRNA delivery. Now the 
question rised why a polycation which is both not biocompatible and not effective should be 
used as conjugate backbone. As a logical consequence it was decided to turn once more 
towards the biodegradable (on its own also ineffective) PLL, not just as proof-of-concept 
polymer but rather as serious backbone alternative to PEI.  
Analog to PEI-PEG-conjugates, DMMAn-Mel-, Mel- and INF-peptide were linked to PLL-PEG 
and siRNA delivery efficiency was studied using Neuro2A-eGFPLuc cells. As expected, PLL 
and PLL-PEG did not mediate siRNA delivery (Fig. 29). In contrast to the results obtained 
with PEI-PEG-conjugates, INF-modified PLL-PEG was not effective in siRNA-delivery. Only 
PLL-PEG-DMMAn-Mel delivered successfully siRNA which resulted in a 90% reduced 
luciferase expression compared to untreated control cells, thus being more effective than the 
corresponding PEI-PEG counterpart. Remarkably PLL-PEG polyplexes displayed a 
considerable protein knockdown when cells were transfected with formulations containing 
control siRNA, indicating carrier toxicity. This observed cytotoxicity was confirmed by MTT 
assay were PLL-PEG polyplexes reduced the metabolic activity (Fig. 31). The finding is 
contrary to popular belief: commonly PEG is applied to reduce toxicity of formulations. But 
PEG improves the solubility and in this way the “bioavailability” of the (potentially toxic) 
polycation is raised. Viewed in this light the cytotoxicity of PLL-PEG polyplexes is 
understandable.  
Although all three applied peptides are lytic, they develop the endosomolytic activity in 
several ways. Melittin is lytic both at pH 5 and 7. Before cleavage of the protecting groups 
DMMAn-Mel shows reduced lytic activity at neutral pH, after deshielding it is obviously lytic at 
both acidic and neutral pH. In comparison to unmodified Mel the lytic activity of DMMAn-Mel 
could be exposed at a later phase of intracellular trafficking. INF is only lytic at acidic pH. If 
the endosome is not acidified, endosomal escape function is not activated. Furthermore, INF 
might be self-limiting: after a first membrane pore formation in the acidic endosomal 
environment the pH can be immediately neutralized due to a fast influx of the neutral cytosol 
/ protons through the just formed leak. This neutralization might inactivate the INF peptide 
before sufficient membrane perforation and escape of the polyplex can take place. 
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Additional, in case of PEI-conjugates a combined effect consisting of PEI’s proton sponge 
capacity and the lytic effect of the peptide can contribute to endosomal escape. Beside 
differences in biophysical properties between the formulations, these mechanistic 
characteristics can contribute to varying delivery activities of the conjugates.  
Size of selected polyplexes was measured by FCS. Related to siRNA polyplexes of PEI-
conjugates, PLL-PEG formed the smallest particles (8 nm, Table 6). Both, PLL-PEG-
DMMAn-Mel and PLL-PEG-Mel formed larger particles at w/w 1 (high polydispersity) and 
small particles at w/w 2 (40 nm and 12 nm, respectively). Because large PLL-PEG-Mel 
polyplexes did not enhance siRNA delivery, the activity of (small and large) PLL-PEG-
DMMAn-Mel polyplexes cannot be explained by a size effect.  
In summary PEGylation and DMMAn-Mel modification of polycations allowed the formation of 
nanosized polyplexes and enabled siRNA delivery despite the fact, that unmodified 
polycations showed no siRNA delivery at all.    
pDNA-transfections were also carried out with the PLL-conjugates on Neuro2A cells (Fig. 
23). PLL-PEG-DMMAn-Mel polyplexes showed an exceptionally high gene transfer activity 
while the other conjugates were ineffective. By MTT assay cytotoxicity was ruled out as 
reason for the great differences in transfection efficiency (Fig. 24).     
In transfection experiments, the polyplex solution is added to the cell culture medium. It might 
be that polyplexes aggregate in the cell culture medium before they reach the cells, which 
could explain differences in transfection experiments. To investigate this effect polyplexes 
were incubated in cell culture medium for 3 h at 37 °C and sizes were measured. While PLL 
and PLL-PEG polyplexes grew in size (from ~ 90 to 180 nm), PLL-PEG-peptide polyplexes 
did not change significantly. Additional cellular polyplex internalization was studied using flow 
cytometry. PLL-PEG polyplexes showed a better uptake than PLL polyplexes, the highest 
degree of internalization was reached by PLL-PEG-peptide polyplexes. There is, therefore, 
every indication that differences in transfection efficiency between PLL-PEG-peptide 
polyplexes are not due to varying aggregation in cell culture medium or an extraordinary high 
internalization degree of PLL-PEG-DMMAn-Mel polyplexes.  Murthy et al. designed a 
polymer which is degraded in the acidic environment of the endosome [152]. They claim that 
the decomposition induces a colloid osmotic disruption of the vesicle which delivery the 
content into the cytosol. The Kataoka group also argues that an acid-labile PEG-nucleic acid 
conjugate releases hundreds of free PEG strands in the acidic endosomal compartment 
which increases the osmotic pressure and eventually induces swelling and disruption of the 
endosome [128]. Basically this is also imaginable when DMMAn-groups are cleaved within 
the endosome; however this is not evidence-based. Hence, apart from differences in 
polyplex size, the reason for the remarkably high nucleic acid delivery activity of DMMAn-
Mel-conjugates remains unsolved. 
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4.1.3 Programmed conjugate containing bioreversibly attached siRNA 
for improved delivery   
To reach the site of action within the target cell, the nucleic acid has to stay associated with 
its carrier during the complete extracellular delivery process. Most polyplex and lipoplex 
formulations are held together electrostatically. A weak point resides in the fact that other 
charged molecules can disrupt such complexes before they reach the target cell. Burke et al. 
demonstrated that both the serum and the extracellular matrix can lead to vector 
disassembly. They observed significant vector unpackaging of systemically injected 
fluorescence-labeled PEI / pDNA polyplexes in the liver, where the labeled DNA was found in 
different areas than the labeled PEI. This obviously negatively affects gene transfer efficiency 
[52]. The work of Buyens et al. reveals the same weak point. They developed a method 
based on fluorescence correlation spectroscopy to study the dissociation of siRNA 
complexes in human serum. The work demonstrates that nonpegylated and pegylated siRNA 
liposome complexes undergo fast disassembly in full serum. Similar observations were made 
for PEI / siRNA polyplexes [53].  Vector unpacking is more likely a problem in case of siRNA 
in comparison with pDNA, as the far larger number of negative charges of pDNA stabilizes 
the interelectrolyte complex [54;55]. 
To overcome this drawback a conjugate containing covalently attached siRNA was 
synthesized and tested for siRNA delivery activity. Luciferase siRNA was linked via disulfide 
bond to PLL-PEG-DMMAn-Mel. All needful domains (PEG, pH-responsive lytic peptide, 
polycation, siRNA) are assembled in one single conjugate, which is an alternative to the 
conventional modular building set approach where e.g. 10% PLL, 10% PLL-PEG and 80% 
PLL-DMMAn-Mel are mixed and complexed with the appropriate amount of siRNA. The all-
in-one solution guarantees optimal codelivery of all functional domains, it circumvents 
disintegration. Additional apparently no “free” polymer is present in the formulation. Usually 
polyplexes are prepared with an excess of polycation, thus containing not with nucleic acid 
associated polymer. Boeckle et al. proved that free polycations cause a higher cellular and 
systemic toxicity of the formulation [153]. The reverse of the medal is that changes in the 
carrier design (such as a higher PEG content, a varying polycation to siRNA ratio or another 
siRNA target sequence) can be only realized by a new resynthesis of the complete 
conjugate. 
As demonstrated in siRNA transfection experiments, the polycation to siRNA ratio has a 
great impact on delivery efficiency and cytotoxicity. Because PLL-PEG-DMMAn-Mel showed 
good siRNA delivery activity at w/w ratio of 2, it was decided to synthesize a similar 
composed conjugate containing covalently attached siRNA. At w/w ratio of 2, 2 µg PLL (as 
hydrobromide) is conjugated with 1 µg siRNA. An overall net positive charge is guaranteed 
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because ~ 9.5 nmol positive charges (lysine’s primary amines) come up against ~ 3 nmol 
negative charges (siRNA phosphates). For two principal reasons this is an important 
characteristic of the conjugate. On the one hand a positive charge is necessary for 
interaction with the negatively charged cell surface and consequently internalization. This is 
of particular importance because no targeting ligand is included into the conjugate. On the 
other hand complexation in addition to the covalent linkage is useful because a siRNA with a 
conventional backbone was used. Conventional siRNA is acceptable for most applications a 
serum-free environment, but a relatively short bioavailability of free siRNA in vivo or in a 
serum-containing environment limits the potential. Complexation protects the nucleic acid 
against degradation through RNAses. Instead of the conventional siRNA, a nuclease-
resistant siRNA containing a phosphothioate backbone could be used, making complexation 
needless regarding this issue. Basically, if mentioned aspects are considered, also a higher 
siRNA loading degree or a smaller polycation backbone is imaginable, generating neutral or 
negatively charged siRNA-conjugates.  
To avoid aggregation of PLL-PEG with thiol-modified siRNA, the synthesis was carried out at 
high NaCl concentration [55]. First siRNA was conjugated to PLL-PEG-PDP. Afterwards, 
without preceding purification, DMMAn-Mel was added to the mixture. Finally the conjugate 
was purified by SEC purification using an eluent buffer containing a high salt concentration. It 
has to be mentioned, that not all PDP-groups could be loaded with DMMAn-Mel peptide. This 
is possible due to the steric hindrance effect of the siRNA molecule in combination with the 
flexible PEG chain which hampers DMMAn-Mel coupling. In general determination of peptide 
loading ratio or PEGylation degree of the synthesized conjugate is complex: by H-NMR or 
pyridine-2-thione-release assay obtained information does not represent the actual 
composition of each single conjugate, the calculations are approximate values based on 
calculations with average molecular weights. For instance the starting material for itself, PLL, 
is not a higly defined molecule, it is a mixture of polylysine polymers with different chain 
lengths. Hence, the molecular weight of the starting material, which is used as basis for 
subsequent calculations, is already an approximate value. However the calculated theoretical 
compositions are suitable to compare conjugates among each other, because for all 
synthesized carriers the same theoretical basics were applied.  
The purification performance was proven by agarose gel electrophoresis. If uncoupled siRNA 
could not be separated from the conjugate with SEC, it would be ionically complexed with the 
PLL-backbone. As a consequence uncoupled siRNA would not be released during gel 
electrophoresis; it would not run into the gel and stay undetected. To deal with this issue 
heparin was added to the conjugate. Heparin, a natural polyanion, dissasembles nucleic acid 
polyplexes and makes sure that free siRNA is released from the conjugate. As demonstrated 
purification was successful, uncoupled siRNA was only found in peak 2 (Fig. 37). To verify 
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that siRNA was linked to the PLL-PEG-conjugate and to quantitate the amount of the same, 
the disulfide bond has to be cleaved. Without disulfide reduction, also in the presence of 
heparin no siRNA would run into the gel. In other words: without reductive intracellular 
environment, also heparane sulfates and other negatively charged macromolecules cannot 
lead to vector unpackaging. Accordingly both TCEP and heparin had to be applied to release 
siRNA from the conjugate. In comparison, a conventional PLL / siRNA polyplex was 
destroyed by addition of heparin alone (Fig. 39).     
Directly after SEC elution in 1 M NaCl buffer, conjugates or more precisely particles had a 
size of 80 nm. After snap-freezing and thawing size grew to ~ 150 nm. The Mirus Bio 
Corporation published a conjugate, named polyconjugate, containing pH-responsive 
PEGylation, covalently attached siRNA and targeting ligands were the main fraction (> 95%)  
had a size of 10 nm, making is substantially smaller than the PLL-PEG-DMMAn-Mel-siRNA 
conjugate [113]. While PLL-PEG-DMMAn-Mel-siRNA contained only one PEG chain per 
polycation, the polyconjugate had a higher degree of PEGylation. Among other things this 
can contribute to the observed size differences. At first appearance it is surprising that 
electrostatically formed PLL-PEG-DMMAn-Mel siRNA polyplexes were smaller in size (40 
nm) in comparison with PLL-PEG-DMMAn-Mel-siRNA. However the polyplexes were formed 
at a siRNA concentration of 0.02 mg/ml. In contrast the conjugate containing covalently 
attached siRNA had a final siRNA concentration of ~ 0.25 mg/ml. When PLL-PEG-DMMAn-
Mel siRNA polyplexes were formed at this siRNA concentration, polyplexes were also larger 
in size (~ 150 nm).  
To evaluate the gene silencing potential of PLL-PEG-DMMAn-Mel-siRNA, transfection 
experiments were performed in Neuro2A cells stably transfected with the eGFPLuc vector. 
siRNA delivery activity was compared with electrostatic PLL-PEG-DMMAn-Mel polyplexes 
formed at w/w 2 with either luciferase or control siRNA (Fig. 37). Using the conjugate, a 
dose-dependent reduction of luciferase activity was observed with approximately 80% 
reduction at 0.125 µg siRNA and over 90% at 0.5 µg siRNA per well. The knockdown 
observed with the electrostatic polyplexes was similar, demonstrating that covalent 
attachment of siRNA did not weaken the siRNA delivery efficiency of the polycationic carrier. 
Transfection with control siRNA complexed to PLL-PEG-DMMAn-Mel at w/w 2 and with a 
conjugate containing covalently attached control siRNA did not influence luciferase 
expression at siRNA doses of up to 0.75 µg. Only transfection with the highest siRNA dose of 
1µg resulted in a 30% reduction of luciferase expression, indicating unspecific knockdown / 
carrier toxicity. To clarify this finding, the cellular viabilities were determined 2 days following 
treatment with the siRNA formulations (Fig. 38). Significant toxicity began to manifest only at 
the highest siRNA dose with both formulations (1 µg), confirming the transfection results 
obtained with polyplexes containing control siRNA. 
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To elucidate the process of delivery with the siRNA conjugate, it was tested if physiological 
glutathione concentrations can induce cleavage of the disulfide bond and lead to siRNA 
release. To monitor the conjugate purification and to examine the siRNA content, TCEP was 
used in the gel electrophoresis studies to cleave the bound siRNA (Fig. 39). TCEP is a 
powerful and irreversible reductant which is stable in aqueous, acidic, and basic solutions. 
However in the cytoplasm only glutathione (GSH) is present as natural reducing agent. 
Glutathione is a tripeptide which can be synthesized from cysteine, glutamate and glycine. In 
cells, the majority of the total glutathione pool is in the reduced form GSH; less exists in the 
oxidized disulfide form (GSSG). To clarify if physiological cytoplasmatic GSH concentrations 
(1 – 10 mM) can cleave the siRNA-connecting disulfide bond, the conjugate was incubated 
for 1 hour at 37 °C with appropriate GSH concentrations. Heparin was added for polyplex 
disassembly and agarose gel shift using EtBr staining was performed after incubation. As 
shown, after incubation with GSH-concentrations of 1.25 to 5 mM, released siRNA could be 
detected (Fig. 39), suggesting that siRNA cleavage of the conjugate may occur in the cellular 
environment. Based on these observations, cleavage of the siRNA before RNA-inducing 
silencing complex formation is likely. We do not know formally whether disulfide cleavage is 
required for activity. Derfus et al. synthesized quantum dots containing covalently bound 
siRNA. Reversibly attached siRNA by disulfide cross-linkers showed greater silencing 
efficiency than siRNA attached by a nonreducible thioether linkage, which also suggests that 
disulfide cleavage in the intracellular takes place and that release of the siRNA may be 
advantageous [58;154].  
In summary, the bioresponsive endosomolytic PLL-PEG-DMMAn-Mel-siRNA conjugate 
showed good in vitro protein knockdown activity. Covalent attachment of siRNA improved 
stability of the siRNA carrier against natural occurring polyanions like heparin. In addition to 
the dynamic endosomolytic activity, cytosolic glutathione levels trigger the programmed 
cleavage of the disulfide linkage and enable release of the siRNA.  
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5 Conclusion and Outlook 
Overall, application of DMMAn-Mel strongly enhanced nucleic acid delivery efficiency of the 
polycations PLL and PEI. PrePEGylation of the polycations before peptide attachment 
prevented polyplex aggregation and allowed the formation of nanosized particles. 
Remarkably, despite big differences of the unmodified polycations PLL and PEI in pDNA 
transfer activity, pDNA transfer activity of PLL-PEG-DMMAn-Mel was similar to that for the 
PEI analogue and even better in the case of siRNA transfer. But unlike the PEI analogue, 
PLL has the additional advantage of being biodegradable. Conjugation of DMMAn-Mel (in 
contrast to unmasked melittin or PEGylation only) lowered the in vitro cytotoxicity of the 
polycations. These findings might have implication for the selection of novel polymers for 
siRNA delivery: polycations with favorable basic characteristics such as nucleic acid binding, 
compaction, protection and biocompatibility, but poor delivery activity which obviously would 
fail in high-throughput screenings might nevertheless be converted into highly efficient siRNA 
carriers. 
The most promising conjugate for siRNA delivery (PLL-PEG-DMMAn-Mel-siRNA) is 
equipped with pathbreaking features. First of all the carrier consists of several components 
with specialized functions (PEG for solubilization and shielding, degradable polycation for 
nucleic acid compaction and protection, and reversible masked lytic domain for endosomal 
release). This modular design takes into account that the nucleic carrier has to fulfill various 
tasks during the process of nucleic acid delivery. Furthermore the siRNA is not only 
complexed electrostatically but also bound covalently to the carrier. This feature guarantees 
enhanced carrier stability on the way to its intracellular site of action. Finally the conjugate 
works in a dynamic virus-like manner: pH- and redox-gradients are exploited to trigger 
endosomal lytic activity and release of the siRNA in the cytosol. This programmed “smart” 
behavior allows the drug carrier to adapt to the unique needs of the different sequentiel 
delivery barriers, which is a key issue in the development of highly effective nucleic acid 
delivery devices.   
Beside improvements including addition of a targeting ligand to increase the specifity or 
optimized shielding of the conjugate, one general issue in the field of polymer drug delivery 
has to be adressed in future work: improved chemistry is necessary to provide monodisperse 
conjugate structures with defined size, topology and functional domain location. A highly 
defined structure and arrangement of the carrier components (e.g. PEG chain, lytic peptides) 
is not only important for meaningful structure-activity-relationships, also on the way from the 
lab bench to the bedside pharmaceutical regulatory requirements have to be met. In 
combination with enhanced delivery efficiency, polymeric nucleic acid therapeutics could 
feed the clinical development pipelines in the future. 
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6 Summary 
Nucleic acid-based therapies provide hope for treating various diseases including cancer and 
a number of inherent disorders. Many disease-causing proteins thought to be “undrugable” 
could now be targeted by therapeutic gene silencing. However the lack of efficient delivery 
systems is still limiting the full therapeutic potential of pDNA and siRNA. Poor endosomal 
release is one major barrier of nucleic acid delivery. Natural organisms like viruses have 
developed strategies to escape from the endosome and thus avoid degradation in the acidic 
endosomal compartment. Hence viruses can be seen as highly efficient model delivery 
systems. 
Aim of the thesis was to improve endosomal escape and transfection efficiency of polycation-
based nucleic acid carriers. Endosomolytic polyethylenimine-melittin conjugates have shown 
enhanced gene transfer efficiency; however, due to their general membrane destabilizing 
properties, cytotoxicity limits their application. To overcome this drawback a polycation was 
grafted with a reversibly masked pH-responsive lytic peptide. Melittin was modified with 
dimethylmaleic anhydride (DMMAn) and covalently coupled to polylysine (PLL). Membrane 
lytic activity was analyzed after incubation at neutral or endosomal pH. Transfection 
experiments using a luciferase reporter gene were carried out. Cellular cytotoxicity was 
analyzed by measurement of membrane integrity and metabolic activity. Covalent 
attachment of DMMAn-modified melittin to PLL resulted in the desired pH-responsive 
conjugate. Reduced lytic activity was observed at neutral pH; after acidic cleavage of the 
protecting groups at pH 5 lytic activity was restored. Acute toxicity was greatly reduced (as 
compared to PLL-Mel or even unmodified PLL) and high gene expression levels were 
obtained. 
The promising concept was transferred to polyethylenimine, one of the most frequently used 
polycations for non-viral gene delivery. However aggregation of the conjugate required 
modification with polyethylene glycol (PEG) for improved solubility and stabilization. 
PrePEGylation allowed the formation of nanosized polyplexes. PEGylated conjugates based 
on PEI and PLL and the lytic peptides melittin, DMMAn-Mel and influenza-derived peptide 
were synthesized and pDNA and siRNA delivery activity was evaluated. In summary, 
application of DMMAn-Mel combined with PEG strongly enhanced pDNA and siRNA delivery 
efficiency of the polycations. Remarkably, despite big differences of the unmodified 
polycations in pDNA transfer activity, pDNA transfer activity of PLL-PEG-DMMAn-Mel was 
similar to that for the PEI analogue and even better in the case of siRNA transfer. But in 
contrast to the PEI analogue, PLL has the additional advantage of being biodegradable.  
Conventional polyplex formulations are held together electrostatically. A weak point resides 
in the fact that other charged biomolecules can disrupt the complexes before they reach the 
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site of action. Recently other research groups demonstrated that both serum and 
extracellular matrix can lead to vector disassembly. To ensure the association of the siRNA 
with the polycationic carrier, a synthesis method to covalently attach the siRNA was 
developed. PLL-PEG-DMMAn-Mel, the most promising conjugate for siRNA delivery as 
found in the gene silencing studies, was covalently modified with siRNA. To enable release 
of the free siRNA in the cytosol a reducible disulfide bond was chosen as linkage. While the 
conventional polyplex could be disassembled by heparin treatment, heparin in combination 
with a reducing agent was necessary to induce release of the siRNA. Heparin treatment 
alone was not sufficient to destroy the conjugate, indicating the improved stability. Release of 
the siRNA under physiological intracellular reducing conditions was evaluated by agarose gel 
electrophoresis studies. The synthesized siRNA-conjugate mediated effective gene silencing 
as effective as the corresponding electrostatic polyplex.  
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7 Appendix 
7.1 Abbreviations 
ATP   Adenosine triphosphate 
CMV   cytomegalovirus 
DLS   dynamic light scattering 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMMAn  dimethylmaleic anhydride 
DMMAn-Mel  DMMAn-modified melittin  
DMSO   dimethyl sulfoxide 
DNTB   5,5'-dithiobis-2-nitrobenzoic acid (Ellman’s reagent) 
DTT   dithiothreitol 
EPR enhanced permeation and retention 
EtBr ethidium bromide 
FBS foetal bovine serum 
FCS fluorescence correlation spectroscopy  
GSH glutathione 
HBG HEPES-buffered glucose 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
INF influenza peptide  
LDH lactate dehydrogenase  
Luc  luciferase 
Mel all-(D)-melittin (with a cysteine residue at the N-terminus) 
mPEG monomethoxy PEG 
MTT methylthiazoletetrazolium 
MW molecular weight 
MWCO molecular weight cut-off 
1H NMR nuclear magnetic resonance 
N/P-ratio molar ratio of nitrogen to DNA phosphate (PLL: molar ratio of epsilon-
amino nitrogen to DNA phosphate) 
PBS phosphate-buffered saline 
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pCMVLuc  plasmid encoding for luciferase under control of the CMV promoter / 
enhancer 
pDNA   plasmid deoxyribonucleic acid 
PEG   polyethylene glycol 
PEI   branched polyethylenimine of a Mw of 25 kDa 
PLL   poly-L-lysine 
PLL-PDP  PLL modified with pyridyldithio-propionate-linkers 
PLL-PEG  PLL modified with PEG 
PLL-PEG-Mel  PLL modified with PEG and Mel  
RISC   RNA-induced silencing complex 
RLU relative light units 
RNA  ribonucleic acid 
RT  room temperature 
SEC size exclusion chromatography  
siRNA small interfering RNA 
SPA-PEG  succinimidylpropionic acid modified PEG 
SPDP succinimidyl 3-(2-pyridyldithio) propionate 
Succ succinic anhydride 
TCEP Tris (2-carboxyethyl) phosphine 
Tf transferrin 
TNBS trinitrobenzenesulfonic acid 
w/w   weight to weight ratio (e.g. of conjugate to nucleic acid)  
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7.2 Publications 
7.2.1 Original papers 
• Martin Meyer, Alexander Philipp, Reza Oskuee, Claudia Schmidt and  Ernst Wagner: 
Breathing life into polycations: functionalization with pH-responsive endosomolytic 
peptides and polyethylene glycol enables siRNA delivery, J. Am. Chem. Soc. 2008 
Mar  
• Martin Meyer, Arkadi Zintchenko, Manfred Ogris and Ernst Wagner: A dimethylmaleic 
acid-melittin-polylysine conjugate with reduced toxicity, pH-triggered endosomolytic 
activity and enhanced gene transfer potential, J. Gene Med. 2007 Sep 
• Martin Meyer, Christian Dohmen, Alexander Philipp, Ernst Wagner: Dynamic siRNA –
polymer conjugate (tentative title), in preparation. 
• Kevin Buyens, Martin Meyer, Ernst Wagner, Joseph Demeester, Stefaan C. De 
Smedt and Niek N. Sanders: Fluorescence Fluctuation Spectroscopy: a powerful tool 
to monitor the disassembly of polymer based siRNA delivery systems in serum 
(tentative title), in preparation. 
7.2.2 Reviews 
• Alexander Philipp, Martin Meyer and Ernst Wagner: Extracellular Targeting of 
Synthetic Therapeutic Nucleic Acid Formulations, Curr. Gene Ther. 2008 Oct 
• Martin Meyer and Ernst Wagner: pH-responsive shielding of non-viral gene vectors, 
Expert Opin. Drug Deliv. 2006 Sep 
• Martin Meyer and Ernst Wagner: Recent developments in the application of plasmid 
DNA-based vectors and small interfering RNA therapeutics for cancer, Hum. Gene 
Ther. 2006 Nov 
7.2.3 Book chapter 
• Martin Meyer, Gururaj Rao, Ke Ren and Jeffrey Hughes: Pharmacokinetics of Viral 
and Non-Viral Gene Delivery Vectors, in: Pharmacokinetics and Pharmacodynamics 
of Biotech Drugs, Wiley-VCH, Weinheim, 2006 Sep  
7.2.4 Poster presentations 
• Alexander Philipp, Martin Meyer, Arkadi Zintchenko, Manfred Ogris, Christian Plank 
and Ernst Wagner: Programmed Endosomolytic Conjugates for pDNA and siRNA 
delivery, ESGCT 15th Annual Congress, Rotterdam, The Netherlands, 2007 Oct 
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• Martin Meyer, Arkadi Zintchenko, Alexander Philipp, Manfred Ogris, Christian Plank 
and Ernst Wagner: Bioresponsive Endosomolytic Conjugates for DNA and siRNA 
Delivery, ASGT 10th Annual Meeting, Seattle, USA, 2007 June 
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